Perspectives in Cell- and Gene-Based Medicines
University Campus Westend, Hörsaalzentrum, Frankfurt/M., Germany

March 15-17, 2012

Program

A joint Conference of the
18th Annual Meeting of the German Society for Gene Therapy (DG-GT)

Perspective Conference of the Stiftung Hämotherapie-Forschung on the Role of Haemotherapy and Transfusion Medicine

1st Symposium of the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT)

www.cgm-frankfurt2012.de
Meeting Supporters

Stiftung Hämostherapie-Forschung

Boehringer Ingelheim Stiftung

Deutsche Forschungsgemeinschaft (DFG)

Deutsches Rotes Kreuz

G. Speyer Haus

Hans und Wolfgang Schleussner-Stiftung

International Society of Blood Transfusion

Milenyi Biotec

PlasmidFactory

MERCK

SANOFI

HESSEN

LOEWE – Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz

CONSARCTIC

SPP1230

Human Gene Therapy

Human Gene Therapy Methods
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Addresses</td>
<td>4</td>
</tr>
<tr>
<td>General Information</td>
<td>7</td>
</tr>
<tr>
<td>Technical Details for Speakers</td>
<td>12</td>
</tr>
<tr>
<td>Information for the Poster Exhibition</td>
<td>13</td>
</tr>
<tr>
<td>Schedule</td>
<td>14</td>
</tr>
<tr>
<td><strong>Program</strong></td>
<td></td>
</tr>
<tr>
<td>Thursday, March 15</td>
<td>16</td>
</tr>
<tr>
<td>Friday, March 16</td>
<td>18</td>
</tr>
<tr>
<td>Saturday, March 17</td>
<td>26</td>
</tr>
<tr>
<td>Poster Exhibition</td>
<td>27</td>
</tr>
<tr>
<td>Presenters / Chairs</td>
<td>38</td>
</tr>
<tr>
<td>Exhibition Plan</td>
<td>48</td>
</tr>
<tr>
<td>Directions Campus Westend</td>
<td>51</td>
</tr>
<tr>
<td>Public Transportation</td>
<td>52</td>
</tr>
</tbody>
</table>
Dear colleagues and friends,

on behalf of the organizing committee, it is our pleasure to welcome you to Frankfurt for the international meeting “Perspectives in Cell and Gene based Medicines”. The meeting is co-organized by the German Society of Gene Therapy (DG-GT), the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT-Frankfurt) and the Foundation for Hemotherapy Research (Stiftung Hämotherapie-Forschung).

We have focused the meeting on Cell- and Gene-based Medicines, as gene and cell therapeutic principles and especially the combination of both fields, offers excellent perspectives for improved treatment of a broad spectrum of diseases in the future and represents an important basis for regenerative medicine. Also the identification of new sources of adult stem cells or the ex vivo generation of pluripotent (iPS) cells with unlimited regenerative capacity is of major interest for cell and gene therapy.

The meeting “Perspectives in Cell and Gene based Medicines” will touch all these aspects and will offer the possibility, in particular to young scientists, to discuss topics related to cell- and gene-based medicines with experts in the field. We have also included a session on regulatory issues related to the production and processing of cell and gene-based products intended for medical applications according to the current legislation. This satellite meeting is organized by the EU - Good Manufacturing Practice (GMP) academic group, an EU-supported academic organization dedicated to the dissemination and application of the EU GMP guidelines at the academic level.

We have invited many international experts highly recognized in the field, who will discuss new developments and prospective expectations of cell- and gene-based medicines for the treatment of a wide variety of diseases. Young scientists will have the opportunity to present their work as short oral or poster presentations and discuss their results with the more senior experts in the field. An excellent opportunity for this is the Scientific Science Night, Friday evening. We encourage you to actively participate in the meeting and take this unique opportunity to network with colleagues in this dynamic and exciting field of research.

Frankfurt offers a great diversity of attractions including a world-class opera, magnificent theaters, wonderful museums and excellent restaurants and pubs. The Campus Westend, where the meeting is taking place, impresses by a modern architecture which includes the ‘IG Farben” and the ‘Casino’ buildings which have an eventful history. Built in the 1920s, the complex was the largest and most modern office building all over Europe at that time. After the Second World War, it was used as the American headquarters of General Eisenhower. Nowadays, as residence of the Goethe-University, the area with its spacious parks is one of the most beautiful university campuses of Germany.

We look forward to sharing with you an outstanding and memorable scientific event. We would like to extend our gratitude to all contributors, sponsors and exhibitors and to everyone who assisted with the meeting organization and management.

Erhard Seifried
Stefanie Dimmeler
Manuel Grez
Dear participants, ladies and gentlemen,

as president of the “Foundation of Haemotherapy Research”, which is the co-initiator and main sponsor of this meeting, I cordially welcome you to this very topical and most promising perspective conference on the latest results in research concerning cell- and gene-based medicines.

Haemotherapy as a synonyme of Transfusion Medicine is predestined to form a link between experimental science, genetic and cellular engineering and technology on the one hand and individual treatment of patients in different clinics on the other. This is because all technical prerequisites and tools for preparative purposes of cell- and gene-derived therapeutic agents are in principle available in transfusion medical institutes.

Moreover, appreciable knowledge, skill and experience in good manufacturing practices of those agents form a daily requirement for the qualification of specialized physicians and technologists, who are involved in the preparation and use of all blood derived therapeutics.

The statutory purpose of our foundation is to support the research on the development of haemotherapy on the one hand as well as the search and promotion of young and highly talented scientists on the other especially in and for the field of haemotherapy, topically with particular reference to cell- and gene-based medicines.

This seems to us to be the most important prerequisite for the future profiling and quality assurance of our special branch, namely haemotherapy and transfusion medicine.

In this context - for supporting reasons - I only mention a current advertisement for a tenure track professorship or junior professorship on experimental cell-therapy at the University of Bonn, which is sponsored by our foundation. Furthermore, research fellowships are granted by our foundation to promote young highly qualified scientists in the field of haemotherapy research.

In the framework of our perspective conference several opportunities - such as the science nights - are offered to intensify the communication between many national and international prominent scientific experts on the one side and young interested physicians and even students beginning their scientific work on the other.

Accordingly, the aim of our conference would be completely achieved, if - by means of inspiration and enthusiasm for the topics of our meeting - the beginning or continuation of scientific communication and exchange between younger and more experienced scientists would have been successfully accomplished. In this spirit, I wish you a delightful experience throughout all three days of our event, with a lot of discussions contributing to amplify our scientific network, generation and exchange of new ideas included.

Sincerely,

Peter Hanfland
Dear Delegates,

I would like to welcome you most cordially to Goethe-Universität Frankfurt in Hessen, a centre of science and higher education. The life sciences and biotechnology are among the key technologies which will shape the 21st century. They will contribute to the solution of medical and technical problems and will have far-reaching impact on healthcare for people, the management of environmental hazards and society as a whole.

In cell and gene therapy there are a large number of challenges that can only be mastered by close cooperation between scientists at universities and research institutes and through an exchange of experience with industrial companies. As a centre of higher education and research, Hessen will have a key role to play. The state government of Hessen is making targeted investments in education, research and the rapid transfer of innovative ideas to practical applications and everyday products. Among other things, the state government has given a strong signal that has been noted throughout Germany through its research subsidy programme “LOEWE” and investments totalling 410 million euros in this legislative period alone. Thanks to LOEWE, the scientific and industrial centre of Hessen is being reinforced and becoming more intensively networked. Examples include research cooperation such as that within the LOEWE-Centre for Cell and Gene Therapy (CGT) here in Frankfurt which is supported by the state. Such projects are symbols of the networking of outstanding research at universities and research institutes in Hessen. Both industry and the public benefit from the considerable innovative power of research establishments in Hessen, for example in the form of new drugs, better treatment methods and expert healthcare.

I would like to wish all the participants, our many guests from Germany and other countries, both experts and junior scientists, inspiring scientific discussions, many exciting contacts and a pleasant stay in Hessen. Why not take the opportunity to see part of the unique cultural heritage of our state? I am convinced that you will be enthusiastic.

Eva Kühne-Hörmann
Hessen State Minister of Higher Education, Research and the Arts
Organizers
• German Society for Gene Therapy (DG-GT)
• Perspective Conference of the Foundation of Haemotherapy-Research on the role of Haemotherapy and Transfusion Medicine
• 1st Symposium of the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT)

Host Organization
Klinikum Johann Wolfgang Goethe-Universität Frankfurt am Main
Theodor-Stern-Kai 7, 60690 Frankfurt

Organizing Committee Chairs
• Erhard Seifried
• Stefanie Dimmeler
• Manuel Grez

Corresponding Address
Institute for Transfusion Medicine & Immunohaematology
Goethe University Hospital
German Red Cross Blood Donor Service Baden-Württemberg - Hessen
Sandhofstraße 1, 60528 Frankfurt

Congress Secretary
Dr. med. Jörg Schüttrumpf
Phone: +49 (0)69 67 82-0
Fax: +49 (0)69 67 82-231
info@cgm-frankfurt2012.de

Congress Organization
Kongress- und MesseBüro Lentzsch GmbH,
Gartenstraße 29
61352 Bad Homburg, Germany
Phone: +49 (0) 6172 6796-0
Fax: +49 (0) 6172 6796-26
E-Mail: info@kmb-lentzsch.de
www. kmb-lentzsch.de

Organizing Scientific Committee
• Halvard Bönig,
  Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg - Hessen, Frankfurt
• Christian Brandts,
  Department of Medicine II, Haematology/ Oncology, Goethe-University, Frankfurt
• Stefanie Dimmeler,
  Institute of Cardiovascular Regeneration, Goethe-University, Frankfurt
• Manuel Grez,
  Georg-Speyer-Haus, Frankfurt
• Bernd Groner,
  Georg-Speyer-Haus, Frankfurt
• Holger Hackstein,
  Institute for Clinical Immunology and Transfusion Medicine, University Hospital Giessen, Giessen
• Peter Hanfland,
  Bonn, Foundation of Haemotherapy-Research
- Reinhard Henschler, Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg - Hessen, Frankfurt, and Institute of Transfusion Medicine, Cell Therapeutics and Haematology, Ludwig-Maximilians-University, Munich
- Joachim Koch, Georg-Speyer-Haus, Frankfurt
- Ulrike Köhl, Pediatric Haematology and Oncology, Goethe-University, Frankfurt
- Wolfgang Mayr, University Clinics for Blood Group Serology and Transfusion Medicine, Vienna
- Harald von Melchner, Molecular Hematology, Goethe-University, Frankfurt
- Norbert Müller, Essen, Foundation of Haemotherapy-Research
- Johannes Oldenburg, Institute of Experimental Haematology and Transfusion Medicine, University Hospital, Bonn
- Michael Rieger, Georg-Speyer-Haus, Frankfurt
- Jörg Schüttrumpf, Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg – Hessen, Frankfurt
- Erhard Seifried, Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg - Hessen, Goethe-University, Frankfurt
- Hubert Serve, Department of Medicine II, Haematology/Oncology, Goethe-University, Frankfurt
- Torsten Tonn, German Red Cross Blood Donor Service East, Dresden
- Andreas Zeiher, Department of Medicine II, Cardiology, Goethe-University, Frankfurt
**Venue**
University Campus Westend
Hörsaalzentrum, Grüneburgplatz 1
D-60323 Frankfurt/M., Germany
www.uni-frankfurt.de

**Date**
March 15-17, 2012

**Registration Counter**
March 15  08:00 – 20:30
March 16  07:30 – 18:30
March 17  07:30 – 13:30

Registration Phone
+49 (0)69 79 83 55 51

**Exhibition**
March 15  13:30 – 20:30
March 16  08:30 – 18:00
March 17  09:00 – 13:30

**Website**
http://www.cgm-frankfurt2012.de

**Registration**
Please register online under www.cgm-frankfurt2012.de
If no internet access is available, please contact Kongress- und MesseBüro Lentzsch GmbH
eMail info@kmb-lentzsch.de
Phone + 49 (0)6172 6796 - 0
Fax + 49 (0)6172 6796 - 26

**Registration Fees**

**Late registration (until March 14, 2012):**
- 200 Euro – Academic
- 110 Euro – Student *
- 120 Euro – Workshop EU Academic GMP
- 90 Euro – Student Workshop EU Academic GMP

**Registration Fees on-site Registration**
- 210 EUR – Academic
- 120 EUR – Student
- 130 EUR – Workshop EU Academic GMP
- 100 EUR – Student Workshop EU Academic GMP

**Day Ticket (on-site registration only):**
**Thursday, March 15**
- 100 Euro – Academic
- 70 Euro – Student *

**Friday, March 16**
**Including Science Night**
- 120 Euro – Academic
- 90 Euro – Student *

**Saturday, March 17**
- 80 Euro – Academic
- 50 Euro – Student *

Conference fee includes: conference bag, lunch snack, coffee and catering services.

* Reduced registration fees can only be granted if a valid certificate by the senior consultant or by the university is sent to the congress office via fax or email.
Payment
Payments accepted in EURO only

• By bank transfer
to the following bank account:
Kongress- und MesseBüro
Lentzsch GmbH
Account No. 09 383 6508
Sort Code No. 500 700 24
Deutsche Bank Privat- und Geschäftskunden AG

For international bank transfers:
IBAN: DE49 5007 0024 0093 8365 08
BIC: DEUTDEDBFRA

Banking fees have to be settled by the remitter.

• By credit card
Eurocard, Visa, American Express

Confirmation of Registration / Congress Documents
You will receive a confirmation note after receipt of payment.

Cancellation Policy
If you cancel your registration in writing before February 27, 2012, your full registration fee will be refunded less EUR 20 handling fee. There will be no refund of registration fees for cancellations after February 27, 2012.
Please note the stamped date of receipt by the organising office of Kongress- und MesseBüro Lentzsch GmbH.

Privacy Policy
The data are processed behalf of the University Clinic Frankfurt. For further details regarding the “privacy policy” please visit our homepage www.kmb-lentzsch.de

Liability
Kongress- und MesseBüro Lentzsch GmbH acts as an agent only and is not liable for losses, accidents or damages to persons or objects due to any cause.
This does not apply to the individual liability of persons or companies employed for the social events.
For all tours, excursions, etc, the delegate participates at his own risk. All supplementary agreements by word of mouth are without obligation until confirmed in writing.

Internet / W-LAN
W-LAN access will be provided free of charge at the ground floor/exhibition area.
A limited number of W-LAN access vouchers are available at the media check counter.
Please ask for the access code at the media check counter.
Non-Smoking Congress
The Conference 2012 is a nonsmoking event. Participants are kindly requested to refrain from smoking in the congress venue, including the exhibition area.

Mobile Phones
Delegates are kindly requested to switch off their mobile phones during the sessions.

Duplication or Recording
Any form of duplication of congress material as well as optical and/or acoustical recording (autotaping, digital taping, photography, video) in the sessions is prohibited.

CME Credits
The meeting is certified by the German Landesärztekammer Hessen with the following credit points:
- Thursday, March 15th: 6 points
- Friday, March 16th: 6 points
- Saturday, March 17th: 3 points

In order to receive credit points you have to register each day separately. The certificates can be picked up daily at the registration counter during the afternoon coffee breaks.

Social Program
Thursday, March 15th, 2012:
Get-together, 18:30 – 20:30, in the exhibition area on the ground floor

Friday, March 16th, 2012:
Poster view, 18:30 – 20:00, in the poster exhibition, first floor

Special Science Night, 20:00,
CampusWestend, Saal West
Young scientists meet the Speakers during Dinner for a lively discussion and exchange of ideas.
Participation - EUR 20.00
Additional tickets for accompanying persons EUR 50.00 incl. buffet and drinks
Audiovisual Equipment
All rooms for plenary, oral, special, and educational sessions are equipped with a computer, a beamer and microphones for the speaker, the chairpersons and the audience.

Media-check
The media check is located on the ground floor near the registration desk. Speakers are asked to hand in their Power Point presentation at the latest one hour before the start of the session. If the presentation is scheduled for the morning session then please submit the power point file on the day before.
Use of own laptop computers for the presentation is due to time constrains not possible.

Language
The language of the presentations is English
Information for the Poster Exhibition

Registration
Registration for the congress is required for participation in the poster exhibition.

Location
The poster exhibition will be located on the 1st floor in the foyer. The positioning of the poster will be in correspondence with the numbering of the topic as indicated in the main program. The poster walls are marked with numbers.

Poster Size
The posters should be a maximum of 90 cm wide x 150 cm height. It is absolutely necessary to present the poster in an upright format.

Poster Mounting
Please make sure that your poster is put up on Thursday, March 15th, 2012 from at 12:00 p.m. until 4:00 p.m. All posters will have to be taken down on Saturday, March 17th, 2012 from 1:30 p.m. - 2:30 Mounting material will be provided on site.

Poster View
A poster view and discussion is scheduled for Friday, March 16th from 6:30 p.m. until 20:00 p.m. The poster presenter is kindly requested to be present during the poster view.

Poster Award
All submitted posters are eligible for a “Best Poster Award”. The posters are awarded on Saturday, March 17th at 1:15 p.m. There will be an award for the best 3 posters.
<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>HZ 2</td>
<td>8:30-10:30 Scientifc Session 1</td>
</tr>
<tr>
<td>9:00</td>
<td>8:45-11:00 Educational Session</td>
<td>ISBT Academy 1</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td>HZ 3</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>14:15-14:30 Welcome and opening</td>
<td>14:00-16:00 Scientific Session 3</td>
</tr>
<tr>
<td>14:30</td>
<td>14:30-16:00 Plenary Session 1</td>
<td>Clonality in Normal and Aberrant Regeneration</td>
</tr>
<tr>
<td>15:00</td>
<td>14:30-16:00 Plenary Session 1</td>
<td>Advances in Gene Therapy of Hemophilia</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>16:30-18:30 Plenary Session 2</td>
<td>16:30-18:30 Scientific Session 4</td>
</tr>
<tr>
<td>17:00</td>
<td>16:30-18:30 Plenary Session 2</td>
<td>Modulating Vector Cell Interactions</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>18:30 Get together</td>
<td>Poster View + Drinks</td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Location 1</td>
<td>Location 2</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>8:30-10:30</td>
<td>HZ 8</td>
<td>HZ 11</td>
</tr>
<tr>
<td></td>
<td>Workshop EU Academic GMP</td>
<td>Impact of Regulations on Advanced Cellular Therapies</td>
</tr>
<tr>
<td>Coffee Break + Posters</td>
<td>Coffee Break + Posters</td>
<td></td>
</tr>
<tr>
<td>11:00-13:15</td>
<td>HZ 11</td>
<td>HZ 2</td>
</tr>
<tr>
<td></td>
<td>11:00-13:15 Scientific Session 2b Virotherapy and Cancer Gene Therapy</td>
<td>11:30-13:15 Plenary Session 4 Hematopoietic and Cardiac Gene Therapy</td>
</tr>
<tr>
<td>Lunch + Posters</td>
<td>Lunch + Posters</td>
<td></td>
</tr>
<tr>
<td>14:00-16:00</td>
<td>HZ 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Workshop EU Academic GMP</td>
<td>Impact of Rules on Advanced Cellular Therapies</td>
</tr>
<tr>
<td>Coffee Break + Posters</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Saturday
### Thursday, March 15

#### Educational Session ISBT Academy 1  HZ 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 11:00</td>
<td>Hematopoietic Stem Cell Biology</td>
<td>Chairs: Reinhard Henschler, Munich; Christian Brandts, Frankfurt</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Introduction</td>
<td>The ISBT Perspective, Anne Husebekk, Tromsø</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>The biology of hematopoietic stem cells (HSCs)</td>
<td>Michael Rieger, Frankfurt</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>The stem cell niche</td>
<td>Hartmut Geiger, Ulm</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Principal criteria for donor selection</td>
<td>Gero Hütter, Mannheim</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>How to mobilize stem cells from the bone marrow to peripheral blood?</td>
<td>Halvard Bönig, Frankfurt</td>
</tr>
</tbody>
</table>

#### 11:00 - 11:30 Coffee Break

#### Educational Session ISBT Academy 2  HZ 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 13:30</td>
<td>Finding the Right Donor</td>
<td>Chairs: Carl-Heinz Müller, Ulm; Hans Martin, Frankfurt</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Is the source of stem cells (bone marrow, peripheral blood, or cord blood) of importance in transplantation?</td>
<td>Gesine Bug, Frankfurt</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Stem cell donor search</td>
<td>Carl-Heinz Müller, Ulm</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Matching cells to patients (HLA-Markers)</td>
<td>Wolfgang Mayr, Vienna</td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td>Donation procedure and donor safety</td>
<td>Susanne Bräuninger, Frankfurt</td>
</tr>
</tbody>
</table>

#### 14:15 - 14.30 General Meeting Opening

P. Hanfland, E. Seifried, H. Büning, A. Zeiher
### Thursday, March 15

#### Plenary Session 1  
**HZ 2**

**14:30 - 16:00**  
**Advances in Gene Therapy of Hemophilia**  
Chairs: Erhard Seifried, Frankfurt; Hubert Serve, Frankfurt

- **Inv1**  
  **14:30 - 15:05**  
  **Gene therapy: Genome editing for hemophilia B**  
  Katherine High, Philadelphia

- **Inv2**  
  **15:05 - 15:40**  
  **Advances in gene therapy for hemophilia**  
  Thierry Vandendriessche, Brussels

- **15:40 - 16:00**  
  **DG-GT Best Paper Award 2011**

#### Coffee Break  
**16:00 - 16:30**

#### Plenary Session 2  
**HZ 2**

**16:30 - 18:30**  
**Cellular Plasticity**  
Chairs: Bernd Groner, Frankfurt; Stefanie Dimmeler, Frankfurt

- **Inv3**  
  **16:30 - 16:55**  
  **Cell replacement approaches in the heart**  
  Bernd Fleischmann, Bonn

- **Inv4**  
  **16:55 - 17:20**  
  **Human pluripotent stem cells-derived cardiomyocytes for regenerative medicine**  
  Robert Passier, Leiden

- **Inv5**  
  **17:20 - 17:45**  
  **Cardiomyocyte dedifferentiation and cardiac stem cells during cardiac repair and disease**  
  Thomas Braun, Bad Nauheim

- **Inv6**  
  **17:45 - 18:10**  
  **Cell therapy for osteogenesis imperfecta: Where biology meets therapy**  
  Ed Horwitz, Philadelphia

- **18:10 - 18:30**  
  **LOEWE-CGT Best Abstract Award**

#### Get together  
**18:30 - 20:30**

#### Speakers Dinner (by invitation only)  
**20:00**
**Friday, March 16**

### Scientific Session 1  
**HZ 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 08:30 - 10:30 | **Genome Engineering and Repair**                                     | *CenH3 enhances gene vector maintenance by neo-centromere formation*  
|             | Inv7                                                                | Aloys Schepers, Munich |
| 08:30 - 08:50 | Insertion profiles of transposon based vectors and strategies for targeted transgene insertion | Zoltan Ivics, Langen   |
| 08:50 - 09:10 | Cut and paste - targeted genome engineering using designer nucleases | Toni Cathomen, Hannover |
| 09:10 - 09:30 | Generation of a tumor- and tissue-specific episomal non-viral vector system | Manfred Ogris, Munich |
| 09:30 - 10:18 | Identification of a domain responsible for the dose-dependent antiproliferative and apoptotic effects of Sleeping Beauty transposase | Melanie Galla, Hannover |
| 10:18 - 10:30 | Phenotypic correction of a X-CGD model cell line by targeted genome engineering | Anne-Kathrin Dreyer, Hannover |

### Educational Session ISBT Academy 3  
**HZ 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 08:30 - 10:30 | **Hematopoietic Stem Cell Transplantation and Graft Manipulation**     | *Clinical applicability of stem cells from cord blood for transplantation*  
|             | Educational Session ISBT Academy 3                                   | Franco Locatelli, Pavia |
| 08:30 - 09:00 | Clinical applicability of stem cells from cord blood for transplantation | Franco Locatelli, Pavia |
| 09:00 - 09:30 | How does T-cell depleted grafts affect the clinical outcome of HSC transplantation? | Tobias Feuchtinger, Tübingen |
## Friday, March 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 10:00</td>
<td>Autologous stem cell transplantation</td>
<td>Martin Gramatzki, Kiel</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Reduced intensity conditioning – influence on the patient treatment and clinical outcome.</td>
<td>Dietger W. Niederwieser, Leipzig</td>
</tr>
</tbody>
</table>

### Coffee Break + Poster

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 11:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Scientific Session 2a

#### 11:00 - 13:15

##### iPS, Reprogramming and Hematopoiesis

Chairs: Michael Milson, Heidelberg; Michael Rieger, Frankfurt

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inv10 11:00 - 11:20</td>
<td>“Factor-free” induced pluripotent stem cells for modelling of nanogenetic neutrophil diseases</td>
<td>Axel Schambach, Hannover</td>
</tr>
<tr>
<td>Inv11 11:20 - 11:40</td>
<td>Generating transplantable HSC’s from induced pluripotent stem cells</td>
<td>Niels-Bjarne Woods, Lund</td>
</tr>
<tr>
<td>Inv12 11:40 - 12:00</td>
<td>Defective reprogramming of fibroblasts from Fanconi anemia patients: mechanistic insights and implications for iPS-based therapeutics</td>
<td>Michael Milsom, Heidelberg</td>
</tr>
<tr>
<td>Or2a.1 12:00 - 12:12</td>
<td>Zinc-finger nuclease-mediated correction of RS-SCID</td>
<td>Shamim Rahman, Hannover</td>
</tr>
<tr>
<td>Or2a.2 12:12 - 12:24</td>
<td>Serum- and stromal cell-free generation of embryonic stem cell-derived hematopoietic cells, capable of multilineage repopulation of irradiated immunocompetent mice</td>
<td>Dietrich Armin Lesinski, Hannover</td>
</tr>
<tr>
<td>Or2a.3 12:24 - 12:36</td>
<td>Endogenous LINE-1 retrotransposons are mobilized in human pluripotent stem cells and affect genome stability</td>
<td>Sabine Klawitter, Langen</td>
</tr>
<tr>
<td>Or2a.4 12:36 - 12:48</td>
<td>A ubiquitous chromatin opening element (UCOE) prevents transgene silencing in murine pluripotent cells and their differentiated hematopoietic progeny</td>
<td>Nils Pfaff, Hannover</td>
</tr>
<tr>
<td>Or2a.5 12:48 - 13:00</td>
<td>Activated expression of the chemokine Mig following chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity</td>
<td>Anja Moldenhauer, Ludwigshafen</td>
</tr>
</tbody>
</table>
### Friday, March 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:12</td>
<td>Hematopoietic stem cell fate control by Gadd45 gamma</td>
<td>Frederic B. Thalheimer, Frankfurt</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Scientific Session 2b</strong></td>
<td></td>
<td>HZ 11</td>
</tr>
<tr>
<td>11:00 - 13:15</td>
<td>Virotherapy and Cancer Gene Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dirk Nettelbeck, Heidelberg; Wolfgang Uckert, Berlin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inv13</td>
<td>Next generation enveloped viruses for oncolytic virotherapy</td>
<td>Roberto Cattaneo, Rochester</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Parvoviruses as oncolytic principles in cancer treatment</td>
<td>Jean Rommelaere, Heidelberg</td>
<td></td>
</tr>
<tr>
<td>Inv15</td>
<td>Improving the safety of T cell receptor gene therapy</td>
<td>Wolfgang Uckert, Berlin</td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:10</td>
<td>LCMV-pseudotyped VSV-based systems for treatment of malignant glioma</td>
<td>Alexander Muik, Frankfurt</td>
<td></td>
</tr>
<tr>
<td>Or2b.1</td>
<td>Immunomodulatory transgene armed oncolytic measles virus induces anti tumor immunity</td>
<td>Christian Grossardt, Heidelberg</td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:22</td>
<td>Safety of oncolytic measles-virus-superCD in transgenic mice and rhesus macaques</td>
<td>Iris Völker, Langen</td>
<td></td>
</tr>
<tr>
<td>Or2b.2</td>
<td>Exclusive T cell receptor gene transfer to human CD8+ T cells enhances tumor cell killing</td>
<td>Qi Zhou, Langen</td>
<td></td>
</tr>
<tr>
<td>12:22 - 12:34</td>
<td>Genetic engineering combined with directed evolution for developing efficient oncolytic adenoviruses</td>
<td>Inés Fernández Ulibarri, Heidelberg</td>
<td></td>
</tr>
<tr>
<td>Or2b.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:34 - 12:46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Or2b.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:46 - 12:58</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Or2b.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:58 - 13:10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Scientific Session 5</strong></td>
<td></td>
<td>HZ 4</td>
</tr>
<tr>
<td>11:00 - 13:15</td>
<td>Genetic, Metabolic and Acquired Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Johannes Oldenburg, Bonn; Jörg Schüttrumpf, Frankfurt</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inv22</td>
<td>Gene therapy for the treatment of inhibitor in hemophilia</td>
<td>Valder Arruda, Philadelphia</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inv23</td>
<td>Gene therapy for diabetes</td>
<td>Fatima Bosch, Barcelona</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Friday, March 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inv24</td>
<td>11:40 - 12:00</td>
<td>Adenovirus-associated virus vector – mediated gene transfer in hemophilia B. Follow up and future plans</td>
<td>Edward Tuddenham, London</td>
</tr>
<tr>
<td>Or5.1</td>
<td>12:00 - 12:12</td>
<td>Self-inactivating alpharetroviral vectors for gene therapy: functional evaluation in mice and human X-CGD models</td>
<td>Kerstin Kaufmann, Frankfurt</td>
</tr>
<tr>
<td>Or5.2</td>
<td>12:12 - 12:24</td>
<td>Chitosan nanoparticles for oral gene delivery of FIX to treat haemophilia B</td>
<td>Patricia Quade-Lyssy, Frankfurt</td>
</tr>
<tr>
<td>Or5.3</td>
<td>12:24 - 12:36</td>
<td>rAAV-mediated gene replacement therapy restores vision and delays degeneration in the CNGB1-/- mouse model of retinitis pigmentosa</td>
<td>Susanne koch, munich</td>
</tr>
<tr>
<td>Or5.4</td>
<td>12:36 - 12:48</td>
<td>Anti-apoptotic gene transfer to corneal cells leads to prolonged survival during corneal preservation and after transplantation</td>
<td>Thomas Fuchsluger, Duesseldorf</td>
</tr>
<tr>
<td>Or5.5</td>
<td>12:48 - 13:00</td>
<td>A fully active anti-HIV C peptide with greatly reduced immunogenicity</td>
<td>Lisa Egerer, Innsbruck</td>
</tr>
</tbody>
</table>

### 13:15- 14:00 Lunch + Poster

### Scientific Session 3  HZ 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 16:00</td>
<td>Clonality in Normal and Aberrant Regeneration</td>
<td>Chairs: Christopher Baum, Hannover; Zoltan Ivics, Langen</td>
</tr>
<tr>
<td>Inv16</td>
<td>Prevention of adverse events in the genetic modification of stem cells</td>
<td>Christopher Baum, Hannover</td>
</tr>
<tr>
<td>Inv17</td>
<td>Gene therapy for Wiskott-Aldrich-Syndrome</td>
<td>Christoph Klein, Munich</td>
</tr>
<tr>
<td>Inv18</td>
<td>The genome wide distribution of insertional vectors</td>
<td>Christof von Kalle, Heidelberg</td>
</tr>
<tr>
<td>Or3.1</td>
<td>Hepatic lentiviral gene transfer is associated with mild clonal selection, but not with tumour formation in a serial transplantation mouse model</td>
<td>Ina Rittelmeyer, Hannover</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>14:00 - 16:00</td>
<td><strong>Regenerative Medicine</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Hubert Schrezenmeier, Ulm; Norbert Müller, Essen</td>
<td></td>
</tr>
<tr>
<td>Inv25</td>
<td>Bioreactor systems for expansion and differentiation of human stem cells</td>
<td>Cornelia Kasper, Vienna</td>
</tr>
<tr>
<td>14:00 - 14:20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inv26</td>
<td>Erythroid differentiation of pluripotent stem cells: clinical perspectives</td>
<td>Luc Douay, Paris</td>
</tr>
<tr>
<td>14:20 - 14:40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inv27</td>
<td>Multifunctional polymer matrices for regenerative therapies</td>
<td>Carsten Werner, Dresden</td>
</tr>
<tr>
<td>14:40 - 15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Or6.1</td>
<td>Cardiac extracorporal shock wave application to enhance the efficiency of intracoronary cell therapy in chronic heart failure - results of the randomized, double-blind, placebo-controlled CELLWAVE trial</td>
<td>Birgit Assmus, Frankfurt</td>
</tr>
<tr>
<td>15:00 - 15:12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Or6.2</td>
<td>Implanted human bone marrow-derived mononuclear cells (BMC) improved bone formation and maturation in a large bone defect in rats</td>
<td>Caroline Seebach, Frankfurt</td>
</tr>
<tr>
<td>15:12 - 15:24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Or6.3</td>
<td>Monitoring of iron oxide-PLLA-particle-labeled MSCs in vivo</td>
<td>Natalie Fekete, Ulm</td>
</tr>
<tr>
<td>15:24 - 15:36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Or6.4</td>
<td>AAV2.9 - Thymosin beta 4 mediated neovascularization: role of vessel maturation</td>
<td>Rabea Hinkel, Munich</td>
</tr>
<tr>
<td>15:36 - 15:48</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Protein Epitope Mimetic (PEM) CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than AMD3100 and G-CSF and mobilized cells demonstrate favorable transplantation properties
Darja Karpova, Frankfurt

### 16:00 - 16:30 Coffee Break + Poster

<table>
<thead>
<tr>
<th>Time</th>
<th>Scientific Session 4</th>
<th>HZ 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 18:30</td>
<td><strong>Modulating Vector Cell Interactions</strong>&lt;br&gt;Chairs: Stefan Kochanek, Ulm; Joachim Koch, Frankfurt</td>
<td></td>
</tr>
<tr>
<td>Inv19 16:30 - 16:50</td>
<td>Capsid engineering to tailor host-vector-interactions&lt;br&gt;Hildegard Büning, Cologne</td>
<td></td>
</tr>
<tr>
<td>Inv20 16:50 - 17:10</td>
<td>Restricting gene delivery at the level of cell entry&lt;br&gt;Christian Buchholz, Langen</td>
<td></td>
</tr>
<tr>
<td>Inv21 17:10 - 17:30</td>
<td>A hematopoietic stem cell (HSC) specific microRNA renews gene therapy and gives novel insights into the regulation of HSC homeostasis&lt;br&gt;Bernhard Gentner, Milano</td>
<td></td>
</tr>
<tr>
<td>Or4.1 17:30 - 17:42</td>
<td>A small-molecule-controlled system for efficient pseudotyping of prototype Foamy virus vectors&lt;br&gt;Dirk Lindemann, Dresden</td>
<td></td>
</tr>
<tr>
<td>Or4.2 17:42 - 17:54</td>
<td>Aptazymes for RNA autonomous regulation of gene transfer by replication-deficient and replication-competent vectors&lt;br&gt;Patrick Ketzer, Heidelberg</td>
<td></td>
</tr>
<tr>
<td>Or4.3 17:54 - 18:06</td>
<td>Selective gene transfer to liver sinusoidal endothelial cells upon intravenous vector&lt;br&gt;Tobias Abel, Langen</td>
<td></td>
</tr>
<tr>
<td>Or4.4 18:06 - 18:18</td>
<td>Development and preclinical testing of a myeloid specific lentiviral vector for the gene therapy of chronic granulomatous disease&lt;br&gt;Christian Brendel, Frankfurt</td>
<td></td>
</tr>
<tr>
<td>Or4.5 18:18 - 18:30</td>
<td>Adeno-associated viral vectors induce innate immune responses in human non-parenchymal liver cells&lt;br&gt;Hildegard Büning, Cologne</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Session 7

**16:30 - 18:30**

**Cellular Immune Modulation**

Chairs: Harald Klüter, Mannheim; Halvard Bönig, Frankfurt

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:50</td>
<td>T cell antigen receptor therapy</td>
<td>Matthias Theobald, Mainz</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>Highly purified and minimally manipulated cell preparations for adoptive immunotherapy</td>
<td>Dirk Busch, Munich</td>
</tr>
<tr>
<td>17:10 - 17:30</td>
<td>Respiratory dendritic cells in experimental pneumonia</td>
<td>Holger Hackstein, Giessen</td>
</tr>
<tr>
<td>17:30 - 17:42</td>
<td>Clinical scale generation and functional assessment of cytokine-induced killer cells against acute leukemia and soft tissue sarcoma</td>
<td>Eva Rettinger, Frankfurt</td>
</tr>
<tr>
<td>17:42 - 17:54</td>
<td>High-resolution immunogenetic monitoring of the TCR repertoire</td>
<td>Eliana Ruggiero, Heidelberg</td>
</tr>
<tr>
<td>17:54 - 18:06</td>
<td>Establishment of the reversible peptide-Major Histocompatibility Complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8+ T lymphocytes</td>
<td>Sabine Tischer, Hannover</td>
</tr>
<tr>
<td>18:06 - 18:18</td>
<td>Ligand binding of the human activating natural killer cell receptor NKp30 depends on its stalk domain and the glycosylation status</td>
<td>Jessica Hartmann, Frankfurt</td>
</tr>
<tr>
<td>18:18 - 18:30</td>
<td>Potency and GMP development of SmartDC-TRP2: lentiviral vector-induced dendritic cells for melanoma immunotherapy</td>
<td>Renata Stripecke, Hannover</td>
</tr>
</tbody>
</table>

### DG-GT General Assembly

**18:30 - 19:30**

**18:30 - 20:00**

**Poster View + Drinks**

**20:00**

**SPECIAL SCIENCE NIGHT**

Young Scientists Meet the Speakers during Dinner

Saal West
The Regulation of Advanced Cellular Therapies
3rd workshop: March 16, 2012, HZ 3

Workshop “Regulatory aspects related to Advanced Cellular Therapies” chaired by Ulrike Köhl (Frankfurt), Andrea Hauser (Regensburg) and Martin Hildebrandt (München), including round table discussions with colleagues from European and national authorities, legal advisors and stakeholders from academic and industrial GMP facilities in the context of the EU-FP7 research project: “ACADEMIC GMP”.

8:30 Registration

**Session 1: Introduction**
8:40 Welcome & introduction to the project M. Hildebrandt, U. Köhl

**Session 2: Impact of regulations on advanced cellular therapies**
8:50 Regulatory landscape in ATMPs S. Sethe (Newcastle, UK)
9:10 Safety aspects O. Wildner (Langen, D)
9:30 ATMPs – view of the local authorities I. Astner (Braunschweig, D)
9:50 ATMPs – view of the national authorities R. Sanzenbacher (Langen, D)
10:10 ATMPs – international view P. Salmikangas (Helsinki, SF)
10:30 COFFEE BREAK

11:00 Introduction participants round table discussion U. Köhl, M. Hildebrandt

13:15 LUNCH + POSTER

**Session 3: Impact of rules on advanced cellular therapies**
14:00 Incentive for quality controls in cell-based therapies J. Oostendorp (Leiden, NL)
14:10 New concepts in clinical trials M. Lowdell (London, UK)
14:30 Ethics and regulation J. Namorado (Brussels, B)
14:50 Application of regulation T. Tonn (Dresden, D)
15:10 Introduction participants round table discussion A. Hauser, S. Sethe
16:00 Concluding remarks M. Hildebrandt, U. Köhl, A. Hauser
### Saturday, March 17

#### Plenary Session 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 11:00</td>
<td><strong>Cell-Based Therapeutics</strong>&lt;br&gt;Chairs: Winfried Wels, Frankfurt; Torsten Tonn, Dresden</td>
<td></td>
</tr>
<tr>
<td><strong>Inv31</strong> 09:00 - 09:25</td>
<td>The potential role of VSELs in regenerative medicine</td>
<td>Mariusz Ratajczak, Louisville</td>
</tr>
<tr>
<td><strong>Inv32</strong> 09:25 - 09:50</td>
<td>Progress in haploidentical hematopoietic transplantation</td>
<td>Andrea Velardi, Perugia</td>
</tr>
<tr>
<td><strong>Inv33</strong> 09:50 - 10:15</td>
<td>T-cell based gene therapy for cancer</td>
<td>Chiara Bonini, Milano</td>
</tr>
<tr>
<td><strong>Inv34</strong> 10:15 - 10:40</td>
<td>CARs with extraordinary performance: double engineered T cells for an improved anti-tumor attack</td>
<td>Hinrich Abken, Cologne</td>
</tr>
<tr>
<td><em>10:40 - 10:55</em></td>
<td><strong>DG-GT Best Abstract Award</strong></td>
<td></td>
</tr>
</tbody>
</table>

**11:00 - 11:30 Coffee Break + Poster**

#### Plenary Session 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 13:15</td>
<td><strong>Hematopoietic and Cardiac Gene Therapy</strong>&lt;br&gt;Chairs: Christof von Kalle, Heidelberg, Andreas Zeiher, Frankfurt</td>
<td></td>
</tr>
<tr>
<td><strong>Inv35</strong> 11:30 - 11:55</td>
<td>Gene therapy for primary immunodeficiency: lessons learned</td>
<td>Adrian Thrasher, London</td>
</tr>
<tr>
<td><strong>Inv36</strong> 11:55 - 12:20</td>
<td>Hematopoietic stem cell gene therapy for X-linked adrenoleukodystrophy</td>
<td>Nathalie Cartier, Paris</td>
</tr>
<tr>
<td><strong>Inv37</strong> 12:20 - 12:45</td>
<td>Gene therapy for the treatment of heart failure</td>
<td>Roger Hajjar, New York</td>
</tr>
<tr>
<td><strong>Inv38</strong> 12:45 - 13:10</td>
<td>MicroRNAs: novel therapeutic options in cardiovascular disease</td>
<td>Stefanie Dimmeler, Frankfurt</td>
</tr>
</tbody>
</table>

**13:15 - 13:30 Poster Awards + Concluding Remarks**
### P1  Genome Engineering and Repair

| P1.01 | Extrinsic determinants of ZFN and TALEN-mediated gene disruption  
Nadine Dannemann, Hannover |
|-------|-------------------------------------------------------------------|
| P1.02 | pEPI comes of age - Improvement of a non-viral, episomal vector  
Claudia Hagedorn, Witten |
| P1.03 | The Evolution of a dose controlled Retroviral Protein Transfer System  
Tobias Maetzig, Hannover |
| P1.04 | Development of a site directed gene therapy approach by exploiting the HPRT locus in hematopoietic progenitor cells  
Frank Schnüttgen, Frankfurt |
| P1.05 | Genetic Correction of the Human ΔF508 CFTR Locus Using the Zinc-Finger Nuclease Technology  
Christien Bednarski, Hannover |
| P1.06 | Novel methods of zinc finger nuclease delivery to cells  
Sylwia Bobis-Wozowicz, Hannover |
| P1.07 | Adeno-Associated Virus Vectors Mediated Targeted Genome Editing By Zinc Finger Nucleases  
Kafaitullah Khan, Hannover |
| P1.08 | Minicircle DNA – from construction to performance testing  
Marco Schmeer, Bielefeld |
| P1.09 | Copper-mediated selection of transduced cells by human copper transporter ATP7B  
Nadine Schmitt, Münster |
| P1.10 | Non-viral Gene Delivery by Sleeping Beauty Transposon Vectors for Gene Therapy of Gaucher Disease  
Marta Swierczek, Langen |
| P1.11 | Comparative analysis of ZFNs and TALENs targeting the X-SCID-associated IL2RG locus  
Jamal Al Zu’bei, Hannover |

### P2a  iPS, Reprogramming and Hematopoiesis

| P2a.01 | Patterns Of HERV-K Expression In Malignant And Non-Malignant Pluripotent Stem Cells  
Nina Fuchs, Berlin |
|-------|-------------------------------------------------------------------------------------------------|
| P2a.02 | CXCL9 and IL32 regulate HSC expansion and protect hematopoietic progenitor cells from chemotherapy  
Anja Moldenhauer, Ludwigshafen |
| P2a.03 | Establishing of a pure endothelial cell culture from differentiating murine embryonic stem cells  
Sven Becker, Bad Nauheim |
| P2a.04 | Functional long-term characterization of gene corrected liver disease-specific induced pluripotent stem cells  
Ina Rittelmeyer, Hannover |
| P2a.05 | Hepatic differentiation and in vitro selection of human embryonic stem cells and disease specific human induced pluripotent stem cells  
Malte Sgodda, Hannover |
| P2a.06 | Differentiation Of Spiral Ganglion-Derived Stem Cells Into Neurons Capable Of Reinnervating The Organ Of Corti  
Marc Diensthuber, Frankfurt |
| P2a.07 | The impact of HIV-1 on hematopoietic stem and progenitor cells  
Ralf Dürr, Frankfurt |
| P2a.08 | Induced Pluripotent Stem Cells As An Alternative Source Of Mesenchymal Stem Cells  
Irina Eberle, Frankfurt |
| P2a.09 | Epigenetic mechanisms of PADI4 in hematopoiesis and evaluation as a therapeutic target  
Stephan Kolodziej, Frankfurt |
| P2a.10 | The histone H3-lysine 27 demethylase Jmjd3 is required for mesodermal and cardiac differentiation of embryonic stem cell  
Kisho Ohtani, Frankfurt |
| P2a.11 | The loss of Gαq/11 impairs engraftment of hematopoietic cells  
Maike Rehage, Frankfurt |
| P2a.12 | MCAM expression in human mesenchymal stromal cells regulates proliferation, differentiation, and maintenance of hematopoietic stem cells  
Sebastian Thieme, Dresden |
| P2a.13 | Age-dependent role of Sirt1 in hematopoietic recovery following myeloablation  
Marc Tjwa, Frankfurt |
| P2a.14 | Generation of CNS cell types from PNS stem cells  
Marlen Weber, Frankfurt |
| P2a.15 | Nox2 is Required for the Preservation of the Hematopoietic Stem Cell Pool  
Maren Weisser, Frankfurt |
| P2a.16 | Modeling RUNX1 biallelic mutations associated with AML-M0 and AML-FPD in mice reveals importance of residual Runx1 function  
Kira Behrens, Hamburg |
| P2b | **Virotherapy and Cancer Gene Therapy** |
| P2b.01 | Targeting of CD133-specific tumor stem cells with oncolytic measles virus  
Patricia Bach, Langen |
| P2b.02 | Tumor-Targeting of Adenoviruses in vitro and in vivo by genetic insertion of an EphA2 binding peptide  
Michael Behr, Heidelberg |
| P2b.03 | Armed and Retargeted Oncolytic Measles Virus for Chemovirotherapy of Malignant Melanoma  
Johanna Kaufmann, Heidelberg |
| P2b.04 | Transductional Targeting of oncolytic adenoviruses by CAR-ex-pSia adapter molecules improves therapy of pSia-expressing tumors and reduces viral liver load  
Arnold Kloos, Hannover |
| P2b.05 | Visualization of Active Homing of Mesenchymal Stem Cells into Hepatic Colon Cancer Metastases Using the Sodium Iodide Symporter as Reporter Gene  
Kerstin Knoop, Munich |
| P2b.06 | DARPins allow specific targeting of oncolytic measles viruses to tumor cells overexpressing EGFR  
Jan Hanauer, Langen |
| P2b.07 | Semi-replication-competent Vesicular Stomatitis Virus As A Novel Platform For Oncolytic Virotherapy  
Alexander Muik, Frankfurt |
| P2b.08 | Epidermal growth factor receptor directed delivery of transcriptionally targeted diphtheria toxin A enables suicide gene therapy in disseminated colon cancer  
Manfred Ogris, Munich |
| P2b.09 | Specific knockdown of wnt related targets by siRNA with non-viral delivery vectors reduces growth of disseminated colon cancer  
Manfred Ogris, Munich |
| P2b.10 | Comparison of PAMAM dendrimer and linear polyethylenimine for coating of Adenovirus type 5  
Alexandra Vetter, Munich |
<table>
<thead>
<tr>
<th>Poster Exhibition</th>
</tr>
</thead>
</table>
| **P2b.11** | Parameters for the Production of Measles Virus with regard to Oncolytic Virotherapy  
Katja Weiss, Gießen |
| **P2b.12** | Smac mimetic BV6 sensitize human AML cell lines to Cytarabine induced apoptosis and affects proliferation and differentiation of human hematopoietic stem cells  
Jörg Chromik, Frankfurt |
| **P2b.13** | Genetic inhibition of Taspase1 heterodimerization will not aid to target t(4;11) leukemias  
Dorothée Gößwein, Mainz |
| **P2b.14** | Far Upstream Element Binding Protein 1 (FBP1) as a potential target for therapy of Hepatocellular Carcinoma  
Sabrina Khageh Hosseini, Frankfurt |
| **P2b.15** | miR-143 dependent transgene expression for cancer gene therapy  
Florian Kopp, Munich |
| **P2b.16** | YB-1 Dependent Oncolytic Adenovirus Efficiently Inhibits Tumor Growth in Glioblastoma Cancer Stem Cell Lines in vitro and in vivo  
Ulrike Naumann, Tübingen |
| **P2b.17** | Development Of Specific Inhibitors Against Leukemia By Interfering With AML1/ETO Oligomerization  
Julia Schanda, Frankfurt |
| **P2b.18** | Activation of the human immune system via Toll-like receptors by the oncolytic parovirus H-1 and its combination with chemotherapeutic or targeted agents  
Maike Sieben, Mainz |
| **P2b.19** | MicroRNA-sensitive and Armed Oncolytic Measles Virus for Therapy of Pancreatic Cancer  
Martin Singh, Heidelberg |
| **P2b.20** | T cell receptor gene transfer into hematopoietic stem cells for immunotherapy  
Wolfgang Uckert, Berlin |
| **P2b.21** | Inhibition of STAT5 DNA-binding activity in leukemia by the use of a specifically interfering peptide aptamer construct  
Axel Weber, Frankfurt |
<table>
<thead>
<tr>
<th>P3</th>
<th>Clonality in Normal and Aberrant Regeneration</th>
</tr>
</thead>
</table>
| P3.01 | Haematopoietic reconstitution kinetics after transplantation of gene-marked stem cells on a clonal level  
Kerstin Cornils, Hamburg |
| P3.02 | A Novel Method of Combined Preconditioning and In Vivo Chemoselection Using 6 Thioguanine Alone Results in Highly Efficient Reconstitution of Normal Hematopoiesis with HPRT-deficient Bone Marrow  
Katrin Hacke, Los Angeles |
| P3.03 | Evi1 Activation Leads To Increased Genomic Instability In Hematopoietic Cells  
Andrea Kinner, Frankfurt |
| P3.04 | Effect Of Deacetylase Inhibitor Treatment On Proliferation And Self-Renewal Properties Of Leukemic Stem And Progenitor Cells  
Annette Romanski, Frankfurt |
| P3.05 | Low genotoxicity and flexible pseudotyping of alpharetroviral SIN vectors  
Verena Thies, Hannover |
| P3.06 | High throughput integration site analysis of an X-CGD patient treated with a lentiviral vector  
Simone Scholz, Heidelberg |
| P3.07 | Promoting Hematopoietic Engraftment By Conditioning With Cells Overexpressing A Signaling-defective Thrombopoietin Receptor (Mpl)  
Sabine Wintterle, Hannover |
| P3.08 | Humanized models to assess the genotoxicity of viral vectors in the context of hematopoietic gene therapy and in vivo selection  
Ruhi Phaltane, Hannover |
| P3.09 | Use of the in vitro immortalization assay to quantify the impact of vector design and integration pattern on insertional mutagenesis  
Michael Rothe, Hannover |
| P3.10 | Mature T-cell lymphoma induced by insertional transactivation of the Janus kinase 1 gene after gammaretroviral transduction of mature T lymphocytes  
Tim Heinrich, Frankfurt |
| P3.11 | Molecular Basis of Retroviral Integration Clusters  
Carolin Preiss, Frankfurt |
| P3.12 | Response of Hematopoietic Cells to the Activation of Evi1  
Olga S. Kustikova, Hannover |

| P4 | Modulating Vector Cell Interactions |
| P4.01 | Prototype Foamy Virus Pseudotransduction for Transient and Targeted RNA Transfer  
Martin Hamann, Dresden |
| P4.02 | Reduced Sensitivity Of Measles Virus Glycoprotein Based Lentiviral Targeting Vectors Towards Neutralizing Antibodies  
Sabrina Kneissl, Langen |
| P4.03 | Doxycycline-regulated expression of cytidine deaminase (CDD) mediates myeloprotection and avoids lymphotoxicity in a murine transplant model  
Nico Lachmann, Hannover |
| P4.04 | MicroRNA-150-regulated Vectors Allow Lymphocyte-sparing Transgene Expression In Hematopoietic Gene Therapy  
Sebastian Brennig, Hannover |
| P4.05 | Complete tropism restriction by display of high affinity ligands on adeno-associated viral vectors  
Robert Münch, Langen |
| P4.06 | A second generation lentiviral vector targeting system displays targeting ligands on a type I transmembrane protein  
Anke Rasbach, Langen |
| P4.07 | Development of AAV2-based vector for tissue engineering  
Jessica Sallach, Cologne |
| P4.08 | The regulation of 5-lipoxygenase by microRNAs  
Saskia Busch, Frankfurt |
| P4.09 | Self-complementary AAV vector systems for highly regulated expression of interfering RNA (RNAi) molecules  
Regine Heilbronn, Berlin |
| P4.10 | Development of Safety Improved Lentiviral Vectors Containing Ubiquitous Chromatin Opening Elements  
Uta Müller-Kuller, Frankfurt |
| P4.11 | Methylation of L1Hs promoters is lower on the inactive X, has a tendency of being higher on autosomes in smaller genomes and shows inter-individual variability at some loci  
Heike Singer, Bonn |
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4.12</td>
<td>Hypoxia-induced alternative splicing in endothelial cells</td>
<td>Julia Weigand, Frankfurt</td>
</tr>
<tr>
<td>P4.13</td>
<td>Small molecule dependent ribozymes for conditional gene expression and the controlled release of antagonim RNA</td>
<td>Alexander Wittmann, Frankfurt</td>
</tr>
<tr>
<td>P4.14</td>
<td>In vivo imaging of regulated transgene expression in mice and rat brain</td>
<td>Andrea Maddalena, Göttingen</td>
</tr>
<tr>
<td>P5.01</td>
<td>Age-dependent upregulation of miR-34a controls cardiac apoptosis and function</td>
<td>Reinier Boon, Frankfurt</td>
</tr>
<tr>
<td>P5.02</td>
<td>Calcium Phosphate Nanoparticles: A new Tool for the Transfection of Corneal Endothelial Cells</td>
<td>Thomas Fuchsluger, Duesseldorf</td>
</tr>
<tr>
<td>P5.03</td>
<td>Polymer Coating of Adenoviral Vectors for Effective Systemic Gene Delivery Using the Sodium Iodide Symporter (NIS) as Reporter and Therapy Gene</td>
<td>Geoffrey Grünwald, Munich</td>
</tr>
<tr>
<td>P5.04</td>
<td>Safety And Efficacy Of A Gene Transfer Strategy To Bypass Factor VIII Using Factor IX Variants</td>
<td>Peter Milanov, Dresden</td>
</tr>
<tr>
<td>P5.05</td>
<td>Canalostomy as a surgical approach for cochlear gene therapy in the rat</td>
<td>Davina Gassner, Frankfurt</td>
</tr>
<tr>
<td>P5.06</td>
<td>Development Of K562 Cell Lines Expressing The Fya- And Fyb-Duffy Blood-group Antigen For Studies On The Binding Preferences To Certain Plasmodium Vivax Strains</td>
<td>Peter Milanov, Dresden</td>
</tr>
<tr>
<td>P5.07</td>
<td>Development of a gene trap gene therapy approach enabling the inducible expansion of genetically modified hematopoietic precursor cells</td>
<td>Carolin Nowak, Frankfurt</td>
</tr>
<tr>
<td>P5.08</td>
<td>Comparison Of Chitosan-Based Antisense Oligonucleotide And Sirna For Gene Silencing</td>
<td>Suna Ozbas Turan, Istanbul</td>
</tr>
<tr>
<td>P5.09</td>
<td>Overcoming the paucity of primary XCGD patient cells for research</td>
<td>Shweta Pahujani, Frankfurt</td>
</tr>
<tr>
<td>P5.10</td>
<td>F8 Locus Incorporates Causal Mutations Leading to F8 Deficiency in Patients Without Detectable Mutation in the F8 cDNA</td>
<td>Behnaz Pezeshkpoor, Bonn</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>P5.11</td>
<td>Host-conditioning regimen and transplantation strategy in the genomic instability syndrome ataxia-telangiectasia</td>
<td>Julia Pietzner, Frankfurt</td>
</tr>
<tr>
<td>P5.12</td>
<td>Correction of Fanconi Anemia Cells with Sleeping Beauty Transposons</td>
<td>Esther Grueso, Langen</td>
</tr>
<tr>
<td>P5.13</td>
<td>Magnetic colocalisation of viral vectors and target cells improves transduction efficiency in human haematopoietic cells</td>
<td>Ian Johnston, Bergisch Gladbach</td>
</tr>
<tr>
<td>P5.14</td>
<td>Development of precise oligo (aminoethane) amides for in vivo delivery of siRNA</td>
<td>Raphaela Kläger, Munich</td>
</tr>
<tr>
<td>P5.15</td>
<td>Novel Therapeutic Approach For Treating Ischemic Disease: Control Of MiRNA Function By Ligand-Dependent RNA Regulators</td>
<td>Verena Roppelt, Frankfurt</td>
</tr>
<tr>
<td>P5.16</td>
<td>Development of a new sirna delivery system in the anti-angiogenic gene therapy</td>
<td>Emine Salva, Istanbul</td>
</tr>
<tr>
<td>P5.17</td>
<td>miR-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease</td>
<td>Florian Seeger, Frankfurt</td>
</tr>
<tr>
<td>P5.18</td>
<td>A SIN Gammaretroviral Vector for Gene Therapy of Chronic Granulomatous Disease</td>
<td>Joachim Schwäble, Stefan Stein, Frankfurt</td>
</tr>
<tr>
<td>P5.19</td>
<td>Modified Trimera mice, a new humanized mouse model for gene modified T cells, provide secondary lymphoid structures</td>
<td>Andreas Volk, Frankfurt</td>
</tr>
<tr>
<td>P5.20</td>
<td>Integration Defective Lentiviral Vectors For Sleeping Beauty-Mediated Gene Transfer In Blood Stem Cells: Gene Therapy Of Chronic Granulomatous Disease</td>
<td>Oliver Walisko, Frankfurt</td>
</tr>
<tr>
<td>P6</td>
<td>Regenerative Medicine</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>P6.01</td>
<td>Generation of somatic cells from Mesenchymal Stem Cells (MSCs) as a possible source for tissue repair processes  &lt;br&gt;Sabrina Ehser, Frankfurt</td>
<td></td>
</tr>
<tr>
<td>P6.02</td>
<td>Repair of spinal cord injury using bone marrow stromal cell transfected with adenoviral vector expressing glial derived neurotrophic factor in a rat model  &lt;br&gt;Alireza Biglari, Zanjan</td>
<td></td>
</tr>
<tr>
<td>P6.03</td>
<td>Regeneration Of The Intervertebral Disc (Nucleus Pulposus); Influence Of Various Stimuli On The Differentiation Of Human Mesenchymal Stem Cells Into The Lineage Of NP Cells  &lt;br&gt;Franziska Ehlicke, Giessen</td>
<td></td>
</tr>
<tr>
<td>P6.04</td>
<td>Hampered adipogenic potential of MSC derived from cord blood  &lt;br&gt;Marianna Karagianni, Mannheim</td>
<td></td>
</tr>
<tr>
<td>P6.05</td>
<td>Functional properties of human mesenchymal stem cells (hMSC) derived from multiple sclerosis patients as compared to those of healthy donors  &lt;br&gt;Ibrahim Kassis, Jerusalem</td>
<td></td>
</tr>
<tr>
<td>P6.06</td>
<td>Intracoronary Infusion of Bone Marrow-Derived Mononuclear Cells in Acute Myocardial Infarction: 5 Year Clinical Outcome and MRI Data of the Randomized, Double-Blind, Placebo-Controlled REPAIR-AMI Trial  &lt;br&gt;David M. Leistner, Frankfurt</td>
<td></td>
</tr>
<tr>
<td>P6.07</td>
<td>Microcarrier based expansion process of hMSCs in highly vital and non-differentiated quality  &lt;br&gt;Denise Salzig, Giessen</td>
<td></td>
</tr>
<tr>
<td>P6.08</td>
<td>Investigation of different matrices for the differentiation of human mesenchymal stem cells into nucleus pulposus cells  &lt;br&gt;Alexandra Schmiermund, Giessen</td>
<td></td>
</tr>
<tr>
<td>P6.09</td>
<td>Heparin disrupts the CXCR4 SDF-1 Axis and impairs the Functional Capacity of Bone Marrow-derived Mononuclear Cells (BMC) used for Cardiovascular Repair  &lt;br&gt;Florian Seeger, Frankfurt</td>
<td></td>
</tr>
<tr>
<td>P6.10</td>
<td>Transplantation Of AAV-modified Human Adipose Stromal Cells Overexpressing VEGF Stimulates Revascularization And Blood Flow Recovery In Ischemic Murine Limb  &lt;br&gt;Evgeny Shevchenko, Moscow</td>
<td></td>
</tr>
<tr>
<td>P6.11</td>
<td>Novel enzymes for hMSC detachment in a large scale expansion process  &lt;br&gt;Katharina Cierpka, Giessen</td>
<td></td>
</tr>
</tbody>
</table>
### Cell Separation System for Fully Automated Clinical Scale Separation of CD133+ Cells from Bone Marrow Aspirates
Mike Essl, Bergisch Gladbach  

### Automated clinical scale PBMC generation and NK cell expansion
Markus Granzin, Bergisch Gladbach  

### Semi-automated Production of Platelet Lysate
Karin Plöderl, Linz  

### Studying joint regeneration in the red-spotted newt notophthalmus viridescens
Christiane Knopp, Bad Nauheim  

### Evaluation of the influence of two different hydroxyethyl starch solutions (6 % HES 450 0.7 and 6 % HES 200 0.59) in the processing of Cord Blood
Susanne Suessner, Linz  

### Evaluation of the effectiveness of several antimicrobial treatments in tissue banking
Susanne Suessner, Linz  

### Multinucleated Amniotic Cells by Cell Fusion
Lorna Devkota, Wake Forest  

### Cellular Immune Modulation

#### P7.01 HSP70 peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies
Sabine Tischer, Hannover  

#### P7.02 Insect Cells to Analyze the Individual Interaction Between the Human Activating Natural Killer Cell Receptor NKp30 and its Ligand B7H6
Julia Herrmann, Frankfurt  

#### P7.03 Retargeted Natural Killer Cells for Adoptive Cancer Immunotherapy
Winfried Wels, Frankfurt  

#### P7.04 Immune regeneration under immune suppression: lentivirus-induced dendritic cells co-expressing pp65, GM-CSF and IFN-a for preconditioning the recipient prior to donor lymphocyte infusions
Renata Stripecke, Hannover  

#### P7.05 Immune Suppression by Mesenchymal Stromal Cells (MSCs) is Mediated via Galectin-9
Christopher Ungerer, Frankfurt  

#### P7.06 Generation of retroviral vectors encoding WT1-specific TCRs for the transduction of mature T cells
Martina Anzaghe, Frankfurt
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P7.07</td>
<td>Activation of allogeneic NK cells to overcome tumour immune escape</td>
<td>Eileen Auth, Frankfurt</td>
</tr>
<tr>
<td>P7.08</td>
<td>Kir+ NK cells show increased degranulation activity in KIR-HLA mismatch situations post-stem cell transplantation</td>
<td>Petra Becker, Frankfurt</td>
</tr>
<tr>
<td>P7.09</td>
<td>Influence of the Immunosuppressive Drug Mycophenolate Mofetil on NK cell Functionality after Haploidentical Stem Cell Transplantation</td>
<td>Claudia Brehm, Frankfurt</td>
</tr>
<tr>
<td>P7.10</td>
<td>CTLA-4 antibodies Tremelimunab and Ipilimumab overcome tumor-mediated immunosuppressive effects of CTLA-4 on human dendritic cells</td>
<td>Katrin Göpfert, Mainz</td>
</tr>
<tr>
<td>P7.11</td>
<td>Inhibition of tumor immune escape from NKG2D-dependent NK cell cytotoxicity</td>
<td>Ariane Groth, Frankfurt</td>
</tr>
<tr>
<td>P7.12</td>
<td>Skin triggering of TLR7 modulates respiratory dendritic cells and natural killer cells</td>
<td>Nelli Baal, Giessen</td>
</tr>
<tr>
<td>P7.13</td>
<td>Development of a killer cell immunoglobulin like receptor (KIR) typing assay</td>
<td>Johannes Hennecke, Frankfurt</td>
</tr>
<tr>
<td>P7.14</td>
<td>A soluble fragment of the NKp30 ligand BAG-6 inhibites NK cell cytotoxicity</td>
<td>Janina Kaudeer, Frankfurt</td>
</tr>
<tr>
<td>P7.15</td>
<td>Antigen-specific TCR-modified Treg for treatment of EAE</td>
<td>Elisa Kieback, Berlin</td>
</tr>
<tr>
<td>P7.16</td>
<td>Genetically Modified Natural Killer Cells that Express a Tumor-specific Granzyme B Fusion Protein</td>
<td>Pranav Oberoi, Frankfurt</td>
</tr>
<tr>
<td>P7.17</td>
<td>Characterization of primary and expanded NK cells</td>
<td>Sabine Müller, Bergisch Gladbach</td>
</tr>
<tr>
<td>P7.18</td>
<td>Fully reversible Fab-Streptamer reagents for clinical cell therapy</td>
<td>Christian Stemberger, Munich</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Abel</td>
<td>Tobias</td>
<td>Paul-Ehrlich-Institut, Langen</td>
</tr>
<tr>
<td>Abken</td>
<td>Hinrich</td>
<td>University of Cologne, Center for Molecular Medicine Cologne, Tumor Genetics, Cologne</td>
</tr>
<tr>
<td>AlZu’bi</td>
<td>Jamal</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Anzaghe</td>
<td>Martina</td>
<td>Goethe University Frankfurt, Department of Paediatric, Stem Cell Transplantation, Frankfurt</td>
</tr>
<tr>
<td>Arruda</td>
<td>Valder</td>
<td>The Children’s Hospital of Philadelphia and The University of Pennsylvania School of Medicine, Philadelphia, USA</td>
</tr>
<tr>
<td>Assmus</td>
<td>Birgit</td>
<td>Goethe University Frankfurt, Internal Medicine III, Cardiology, Frankfurt</td>
</tr>
<tr>
<td>Astner</td>
<td>Isabel</td>
<td>Trading Supervision Office, Braunschweig</td>
</tr>
<tr>
<td>Auth</td>
<td>Eileen</td>
<td>Goethe University Frankfurt, Department of Pediatric Hematology, Oncology and Hemostaseology, Frankfurt/Main</td>
</tr>
<tr>
<td>Bach</td>
<td>Patricia</td>
<td>Paul-Ehrlich-Institut, Molecular Biotechnology and Gene Therapy, Langen</td>
</tr>
<tr>
<td>Baum</td>
<td>Christopher</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Becker</td>
<td>Petra Susan</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Becker</td>
<td>Sven</td>
<td>Max-Planck-Institute for Heart and Lung Research, Lung Development and Remodelling, Bad Nauheim</td>
</tr>
<tr>
<td>Bednarski</td>
<td>Christien</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Behr</td>
<td>Michael</td>
<td>German Cancer Research Center, Oncolytic Adenoviruses, Heidelberg</td>
</tr>
<tr>
<td>Behrens</td>
<td>Kira</td>
<td>Heinrich-Pette-Institut, Leipniz Institute for Experimental Virology, Hamburg</td>
</tr>
<tr>
<td>Biglari</td>
<td>Alireza</td>
<td>Zanjan University of Medical Sciences School of Medicine, Department of Genetics and Molecular Medicine, Zanjan, Iran</td>
</tr>
<tr>
<td>Bobis-Wozowicz</td>
<td>Sylwia</td>
<td>Hannover Medical School, Institute of Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Bonini</td>
<td>Chiara</td>
<td>Research Division of Regenerative Medicine, Gene Therapy and Stem Cells, San Raffaele Scientific Institute, Milano, Italy</td>
</tr>
<tr>
<td>Boon</td>
<td>Reinier</td>
<td>Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Frankfurt</td>
</tr>
<tr>
<td>Bosch</td>
<td>Fatima</td>
<td>Universidad Autonoma de Barcelona, Barcelona, Spain</td>
</tr>
<tr>
<td>Brandts</td>
<td>Christian</td>
<td>Goethe University Frankfurt, Internal Medicine II, Haematology/Oncology, Frankfurt</td>
</tr>
<tr>
<td>Braun</td>
<td>Thomas</td>
<td>Max-Planck-Institute for Heart and Lung Research, Cardiac Development and Remodeling, Bad Nauheim</td>
</tr>
<tr>
<td>Brehm</td>
<td>Claudia</td>
<td>Goethe University Frankfurt, Departement of Paediatric, Stem Cell Transplantation, Frankfurt</td>
</tr>
<tr>
<td>Brendel</td>
<td>Christian</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Brennig</td>
<td>Sebastian</td>
<td>Hannover Medical School, REBIRTH Cluster-of-Excellence, RG Reprogramming, Hannover</td>
</tr>
<tr>
<td>Bräuninger</td>
<td>Susanne</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Bönig</td>
<td>Halvard</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Buchholz</td>
<td>Christian</td>
<td>Paul-Ehrlich-Institut, Langen</td>
</tr>
<tr>
<td>Bug</td>
<td>Gesine</td>
<td>Goethe University Frankfurt, Internal Medicine II, Haematology/Oncology, Frankfurt</td>
</tr>
<tr>
<td>Busch</td>
<td>Saskia</td>
<td>Goethe University Frankfurt, Pharmaceutical Chemistry, Frankfurt</td>
</tr>
<tr>
<td>Busch</td>
<td>Dirk</td>
<td>Institute for Medical Microbiology, Immunology and Hygiene, Technical University Munich, Germany</td>
</tr>
<tr>
<td>Büning</td>
<td>Hildegard</td>
<td>University of Cologne, Departement of Internal Medicine I and Center for Molecular Medicine (CMMC), Cologne</td>
</tr>
<tr>
<td>Cartier</td>
<td>Nathalie</td>
<td>Hospital Saint-Vincent de Paul-University Paris Descartes, Paris, France</td>
</tr>
<tr>
<td>Cathomen</td>
<td>Toni</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Cattaneo</td>
<td>Roberto</td>
<td>Virology and Gene Therapy Program, Mayo Clinic, Rochester, USA</td>
</tr>
<tr>
<td>Chromik</td>
<td>Jörg</td>
<td>Goethe University Frankfurt, Institute for Experimental Cancer Research in Paediatric, Frankfurt</td>
</tr>
<tr>
<td>Cierpka</td>
<td>Katharina</td>
<td>University of Applied Science Mittelhessen, Institute of Bioprocess Engineering and Pharmaceutical Technology, Giessen</td>
</tr>
<tr>
<td>Comils</td>
<td>Kerstin</td>
<td>University Medical Centre Hamburg-Eppendorf, Clinic for Stem Cell Transplantation Research Department Cell and Gene Therapy, Hamburg</td>
</tr>
<tr>
<td>Dannemann</td>
<td>Nadine</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Devkota</td>
<td>Lorna</td>
<td>Wake Forest University, NC, USA</td>
</tr>
<tr>
<td>Dickinson</td>
<td>Anne</td>
<td>Department of Haematology, University of Newcastle upon Tyne, UK</td>
</tr>
<tr>
<td>Diensthuber</td>
<td>Marc</td>
<td>Goethe University Frankfurt, Department of Otorhinolaryngology, Frankfurt</td>
</tr>
<tr>
<td>Dimmelar</td>
<td>Stefanie</td>
<td>Goethe University Frankfurt, Institute for Cardiovascular Regeneration,Frankfurt</td>
</tr>
<tr>
<td>Douay</td>
<td>Luc</td>
<td>Hospital Saint Antoine and University Pierre et Marie Curie, Research Center Saint Antoine, Paris, France</td>
</tr>
<tr>
<td>Dreyer</td>
<td>Anne-Kathrin</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Dürr</td>
<td>Ralf</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Eberle</td>
<td>Irina</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Egerer</td>
<td>Lisa</td>
<td>Innsbruck Medical University, Division of Virology, Innsbruck</td>
</tr>
<tr>
<td>Ehlicke</td>
<td>Franziska</td>
<td>University of Applied Science Mittelhessen, Institute of Bioprocess Engineering and Pharmaceutical Technology, Giessen</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ehser</td>
<td>Sabrina</td>
<td>Goethe University Frankfurt, Institute for Cell Biology and Neuroscience</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Molecular Cell Biology and Human Genetics, Frankfurt</td>
</tr>
<tr>
<td>Essl</td>
<td>Mike</td>
<td>Miltenyi Biotec GmbH, Research and Development, Bergisch Gladbach</td>
</tr>
<tr>
<td>Fekete</td>
<td>Natalie</td>
<td>University Ulm, Institute of Transfusion Medicine and Immunogenetics, Ulm</td>
</tr>
<tr>
<td>Fernández Ullo</td>
<td>Inés</td>
<td>German Cancer Research Center, Heidelberg</td>
</tr>
<tr>
<td>Feuchtinger</td>
<td>Tobias</td>
<td>University Hospital Tübingen, Department of Pediatrics and Adolescent Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(General Pediatrics, Hematology and Oncology), Tübingen</td>
</tr>
<tr>
<td>Fleischmann</td>
<td>Bernd</td>
<td>Institut for Physiology I, Life &amp; Brain Center, Universität Bonn, Bonn</td>
</tr>
<tr>
<td>Friedrich</td>
<td>Katrin</td>
<td>Paul-Ehrlich-Institut, Oncolytic Measle Viruses and Vectored Vaccines, Langen</td>
</tr>
<tr>
<td>Fuchs</td>
<td>Nina</td>
<td>Max-Delbrück-Center for Molecular Medicine, Molecular Cell Biology and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gene Therapy, Berlin</td>
</tr>
<tr>
<td>Fuchsluger</td>
<td>Thomas</td>
<td>University Hospital Duesseldorf, Department of Ophthalmology, Duesseldorf</td>
</tr>
<tr>
<td>Galli</td>
<td>Melanie</td>
<td>Hannover Medical School, Hannover</td>
</tr>
<tr>
<td>Gassner</td>
<td>Davina</td>
<td>Goethe University, Departement of Otolaryngology - Head and Neck Surgery,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Frankfurt am Main</td>
</tr>
<tr>
<td>Geiger</td>
<td>Hartmut</td>
<td>University Ulm, Departement of Dermatology, Ulm</td>
</tr>
<tr>
<td>Gentner</td>
<td>Bernhard</td>
<td>San Raffaele Telethon Institute for Gene Therapy, Milano, Italy</td>
</tr>
<tr>
<td>Goebel</td>
<td>Benjamin</td>
<td>Goethe University Frankfurt, Internal Medicine II, Haematology/ Oncology,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Frankfurt</td>
</tr>
<tr>
<td>Gramatzki</td>
<td>Martin</td>
<td>University Hospital Schleswig- Holstein, Department of Hematology and Oncology,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kiel</td>
</tr>
<tr>
<td>Granzin</td>
<td>Markus</td>
<td>Miltenyi Biotec GmbH, Research and Development, Bergisch Gladbach</td>
</tr>
<tr>
<td>Groner</td>
<td>Bernd</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Grossardt</td>
<td>Christian</td>
<td>National Center for Tumor Diseases (NCT) and German Cancer Research Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(DKFZ) Translational Oncology, Heidelberg</td>
</tr>
<tr>
<td>Groth</td>
<td>Ariane</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Grueso</td>
<td>Esther</td>
<td>Paul Ehrlich Institut, Department of Medical Biotechnology, Langen</td>
</tr>
<tr>
<td>Grünwald</td>
<td>Geoffrey</td>
<td>Ludwig Maximilian University of Munich, Department of Internal Medicine II,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Munich</td>
</tr>
<tr>
<td>Gößwein</td>
<td>Dorothée</td>
<td>Johannes- Gutenberg University Mainz, Molecular and Cellular Oncology, Mainz</td>
</tr>
<tr>
<td>Göpfert</td>
<td>Katrin</td>
<td>Johannes- Gutenberg University Mainz, Department of Internal Medicine, Mainz</td>
</tr>
<tr>
<td>Hacke</td>
<td>Katrin</td>
<td>University of California, Los Angeles (UCLA)</td>
</tr>
<tr>
<td>Hackstein</td>
<td>Holger</td>
<td>Justus-Liebig-Universität Giessen, Institute for Clinical Immunology and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transfusion Medicine, Giessen</td>
</tr>
<tr>
<td>Hagedorn</td>
<td>Claudia</td>
<td>University of Witter/Herdecke, Institute for Cell Biology, Witten</td>
</tr>
<tr>
<td>Hajjar</td>
<td>Roger</td>
<td>Cardiovascular Research Institute, Mount Sinai School of Medicine, New York,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hamann</td>
<td>Martin</td>
<td>Dresden Faculty of Medicine Carl Gustav Carus, Technical University Dresden, Institute of Virology, Dresden</td>
</tr>
<tr>
<td>Hanauer</td>
<td>Jan</td>
<td>Paul-Ehrlich-Institut, Oncolytic Measles Viruses and Vectored Vaccines, Langen</td>
</tr>
<tr>
<td>Hanfland</td>
<td>Peter</td>
<td>Bonn, Foundation of Haemotherapy-Research</td>
</tr>
<tr>
<td>Hartmann</td>
<td>Jessica</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Hauser</td>
<td>Andrea</td>
<td>Jose Carreras Center for Somatic Cell Therapy (JCC), University Hospital Regensburg, Germany</td>
</tr>
<tr>
<td>Heilbronn</td>
<td>Regine</td>
<td>Charite Medical School, Campus Benjamin Franklin, Institute of Virology, Berlin</td>
</tr>
<tr>
<td>Heinrich</td>
<td>Tim</td>
<td>Goethe University Frankfurt, Seckenberg Institute of Pathology, Frankfurt</td>
</tr>
<tr>
<td>Hennecke</td>
<td>Johannes</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Henschler</td>
<td>Reinhard</td>
<td>Ludwig Maximilian University of Munich, Departement of Transfusion Medicine, Cell Therapeutics and Haemostasis, Munich</td>
</tr>
<tr>
<td>Herrmann</td>
<td>Julia</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>High</td>
<td>Katherine</td>
<td>Howard Hughes Medical Institute, University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, USA</td>
</tr>
<tr>
<td>Hildebrandt</td>
<td>Martin</td>
<td>Interdisciplinary Center for Cellular Therapy, Technical University Munich, Germany</td>
</tr>
<tr>
<td>Hinkel</td>
<td>Rabea</td>
<td>Ludwig-Maximilians- University Munich, Departement of Internal Medicine I, Munich</td>
</tr>
<tr>
<td>Horwitz</td>
<td>Ed</td>
<td>The Children’s Hospital of Philadelphia and The University of Pennsylvania School of Medicine, Philadelphia, USA</td>
</tr>
<tr>
<td>Hösel</td>
<td>Marianna</td>
<td>University Hospital of Cologne, Clinic I of Internal Medicine, Center for Molecular Medicine Cologne (ZMMK), University of Cologne Laboratory for AAV Vector Development, Cologne</td>
</tr>
<tr>
<td>Husebekk</td>
<td>Anne</td>
<td>Immunology Research Group, Institute of Medical Biology, University of Tromso, Tromso, Norway</td>
</tr>
<tr>
<td>Hütter</td>
<td>Gero</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute Mannheim, Mannheim</td>
</tr>
<tr>
<td>Ivics</td>
<td>Zoltan</td>
<td>Paul-Ehrlich-Institut, Langen</td>
</tr>
<tr>
<td>Johnston</td>
<td>Ian</td>
<td>Miltenyi Biotec GmbH, Research and Development, Bergisch Gladbach</td>
</tr>
<tr>
<td>Karagianni</td>
<td>Marianna</td>
<td>Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim</td>
</tr>
<tr>
<td>Karpova</td>
<td>Darja</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Kasper</td>
<td>Cornelia</td>
<td>University of Natural Resources and Applied Life Sciences, Vienna, Austria</td>
</tr>
<tr>
<td>Kassis</td>
<td>Ibrahim</td>
<td>Hadassah, Hebrew University Medical Center Neurology, Multiple Sclerosis Center, Jerusalem</td>
</tr>
<tr>
<td>Kaudeer</td>
<td>Janina</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Kaufmann</td>
<td>Kerstin</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Kaufmann</td>
<td>Johanna</td>
<td>German Cancer Research Center, Oncolytic Adenoviruses, Heidelberg</td>
</tr>
<tr>
<td>Ketzer</td>
<td>Patrick</td>
<td>Helmholtz University Group Oncolytic Adenoviruses, German Cancer Research Center and Dept. of Dermat., Heidelberg</td>
</tr>
<tr>
<td>Khageh-Hosseini</td>
<td>Sabrina</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Khan</td>
<td>Kafaitullah</td>
<td>Hannover Medical School, Institute of Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Kieback</td>
<td>Elisa</td>
<td>Max-Delbrück-Center for Molecular Medicine, Molecular Cell Biology and Gene Therapy, Berlin</td>
</tr>
<tr>
<td>Kinner</td>
<td>Andrea</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Klawitter</td>
<td>Sabine</td>
<td>Paul-Ehrlich-Institut, Langen</td>
</tr>
<tr>
<td>Klein</td>
<td>Christoph</td>
<td>University Hospital Munic, Departement of Pediatric of Dr. von Haunerschen Pediatric Hospital, Munich</td>
</tr>
<tr>
<td>Kloos</td>
<td>Arnold</td>
<td>Hannover Medical School, Clinic for Gastroenterology, Hepatology and Endocrinology, Hannover</td>
</tr>
<tr>
<td>Kläger</td>
<td>Raphaela</td>
<td>Ludwig Maximilian University of Munich, Department of Pharmacy, Munich</td>
</tr>
<tr>
<td>Klüter</td>
<td>Harald</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute Mannheim, Mannheim</td>
</tr>
<tr>
<td>Kneissl</td>
<td>Sabrina</td>
<td>Paul-Ehrlich-Institut, Molecular Biotechnology and Gene Therapy, Langen</td>
</tr>
<tr>
<td>Knoop</td>
<td>Kerstin</td>
<td>Ludwig Maximilian University of Munich, Department of Internal Medicine II, Munich</td>
</tr>
<tr>
<td>Knopp</td>
<td>Christiane</td>
<td>Justus-Liebig-Universität Giessen, Rheumatology and Clinical Immunology, Bad Nauheim</td>
</tr>
<tr>
<td>Koch</td>
<td>Joachim</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Koch</td>
<td>Susanne</td>
<td>Ludwig Maximilian University of Munich, Department of Pharmacy, Munich</td>
</tr>
<tr>
<td>Kochanek</td>
<td>Stefan</td>
<td>University Hospital Ulm, Division of Gene Therapy, Ulm</td>
</tr>
<tr>
<td>Köhl</td>
<td>Ulrike</td>
<td>Goethe University Frankfurt, Department of Pediatric Hematology, Oncology and Hemostaseology, Frankfurt/Main</td>
</tr>
<tr>
<td>Kolodziej</td>
<td>Stephan</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Kopp</td>
<td>Florian</td>
<td>Ludwig Maximilian University of Munich, Department of Pharmacy, Munich</td>
</tr>
<tr>
<td>Kustikova</td>
<td>Olga</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Lachmann</td>
<td>Nico</td>
<td>Hannover Medical School, RG Reprogramming, Hannover</td>
</tr>
<tr>
<td>Leistner</td>
<td>David M.</td>
<td>Goethe University Frankfurt, Internal Medicine III, Cardiology, Frankfurt</td>
</tr>
<tr>
<td>Lesinski</td>
<td>Dietrich Armin</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Lindemann</td>
<td>Dirk</td>
<td>Dresden Faculty of Medicine Carl Gustav Carus, Technical University Dresden, Institute of Virology, Dresden</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Locatelli</td>
<td>Franco</td>
<td>Departement of Paediatric science, University of Pavia, Pavia, Italy</td>
</tr>
<tr>
<td>Lowdell</td>
<td>Mark</td>
<td>Department of Haematology, University College London Medical School, UK</td>
</tr>
<tr>
<td>Maddalena</td>
<td>Andrea</td>
<td>Göttingen University Medical School, Department of Neurology, Göttingen</td>
</tr>
<tr>
<td>Maetzig</td>
<td>Tobias</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Martin</td>
<td>Hans</td>
<td>Goethe University Frankfurt, Internal Medicine II, Haematology/Oncology, Frankfurt</td>
</tr>
<tr>
<td>Mayr</td>
<td>Wolfgang</td>
<td>Medical University Vienna, Vienna, Austria</td>
</tr>
<tr>
<td>Milanov</td>
<td>Peter</td>
<td>German Red Cross Blood Donor Service East, Institute Dresden, Dresden Faculty of Medicine Carl Gustav Carus, Technical University Dresden</td>
</tr>
<tr>
<td>Milsom</td>
<td>Michael</td>
<td>Heidelberg Institute for Stem Cell Technology and Experimental Medicine (Hi-Stem), Heidelberg</td>
</tr>
<tr>
<td>Moldenhauer</td>
<td>Anja</td>
<td>Clinic Ludwigshafen, Institute of Hemostaseology and Transfusion Medicine, Ludwigshafen</td>
</tr>
<tr>
<td>Muik</td>
<td>Alexander</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Mussolino</td>
<td>Claudio</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Müller</td>
<td>Norbert</td>
<td>Essen, Foundation of Haemotherapy-Research</td>
</tr>
<tr>
<td>Müller</td>
<td>Carheinz</td>
<td>German National Registry of Blood Stem Cell Donors (ZKRD) Ulm, Ulm</td>
</tr>
<tr>
<td>Müller</td>
<td>Sabine</td>
<td>Miltenyi Biotec GmbH, Research and Development, Bergisch Gladbach</td>
</tr>
<tr>
<td>Müller-Kuller</td>
<td>Uta</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Münch</td>
<td>Robert</td>
<td>Paul-Ehrlich-Institut, Langen</td>
</tr>
<tr>
<td>Namorado</td>
<td>Joana</td>
<td>Ethics, Gender Issues, Directorate Health DG RTD, European Commission</td>
</tr>
<tr>
<td>Naumann</td>
<td>Ulrike</td>
<td>Hertie Institute for Clinical Brain Research and Center Neurology, University of Tübingen General Neurology, Tübingen</td>
</tr>
<tr>
<td>Nettelbeck</td>
<td>Dirk</td>
<td>German Cancer Research Center, Heidelberg</td>
</tr>
<tr>
<td>Niederwieser</td>
<td>Dietger</td>
<td>University Hospital Leipzig, Department of Hematology, Oncology and Hemostasis, Leipzig</td>
</tr>
<tr>
<td>Nowak</td>
<td>Carolin</td>
<td>Goethe University Frankfurt, Molecular Hematology, Frankfurt am Main</td>
</tr>
<tr>
<td>Oberoi</td>
<td>Pranav</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Ogris</td>
<td>Manfred</td>
<td>Ludwig Maximilian University of Munich, Department of Pharmacy, Munich</td>
</tr>
<tr>
<td>Ohtani</td>
<td>Kisho</td>
<td>Goethe University Frankfurt, Institute of Cardiovascular Regeneration Center for Molecular Medicine, Frankfurt</td>
</tr>
<tr>
<td>Oldenburg</td>
<td>Johannes</td>
<td>University Hospital Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn</td>
</tr>
<tr>
<td>Oostendorp</td>
<td>Jaap</td>
<td>Leiden University Medical Center, Leiden, The Netherlands</td>
</tr>
<tr>
<td>Ozbas</td>
<td>Turan Suna</td>
<td>Marmara University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Istanbul</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pahujani</td>
<td>Shweta</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Paruzynski</td>
<td>Anna</td>
<td>National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) Translational Oncology, Heidelberg</td>
</tr>
<tr>
<td>Passier</td>
<td>Robert</td>
<td>Department of Anatomy &amp; Embryology, Leiden University Medical Center, Leiden, The Netherlands</td>
</tr>
<tr>
<td>Pearce</td>
<td>Kim</td>
<td>University of Newcastle upon Tyne, UK; Institute of Cellular Medicine, University of Newcastle upon Tyne, UK</td>
</tr>
<tr>
<td>Penzkofer</td>
<td>Daniela</td>
<td>Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Frankfurt</td>
</tr>
<tr>
<td>Pezeshkpoor</td>
<td>Behnaz</td>
<td>University Hospital Bonn, Institute of Experimental Hematology and Transfusion Medicine, Bonn</td>
</tr>
<tr>
<td>Pfaff</td>
<td>Nils</td>
<td>Hannover Medical School, REBIRTH RG Reprogramming, Hannover</td>
</tr>
<tr>
<td>Phaltane</td>
<td>Ruhi</td>
<td>Hannover Medical School, Research Group Reprogramming REBIRTH, Hannover</td>
</tr>
<tr>
<td>Pietzner</td>
<td>Julia</td>
<td>Goethe University Frankfurt, Departement of Paediatric Allergy, Pulmonology and Cystic fibrosis, Frankfurt</td>
</tr>
<tr>
<td>Plöderl</td>
<td>Karin</td>
<td>Red Cross Blood Transfusion Service for Upper Austria, Linz, Austria</td>
</tr>
<tr>
<td>Preiss</td>
<td>Carolin</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Quade-Lyssy</td>
<td>Patricia</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Rahmey</td>
<td>Shamim</td>
<td>Hannover Medical School, Institute of Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Rasbach</td>
<td>Anke</td>
<td>Paul-Ehrlich-Institut, Langen</td>
</tr>
<tr>
<td>Ratajczak</td>
<td>Mariusz</td>
<td>Department of Medicine, Stem Cell Institute at the James Graham Brown Cancer Center, University of Louisville, Louisville, USA</td>
</tr>
<tr>
<td>Rehage</td>
<td>Maike</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Rettinger</td>
<td>Eva</td>
<td>Goethe University Frankfurt, Department of Pediatric Hematology, Oncology and Hemostaseology, Frankfurt/Main</td>
</tr>
<tr>
<td>Rieger</td>
<td>Michael</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Rittelmeyer</td>
<td>Ina</td>
<td>Hannover Medical School, Institute for Gastroenterology, Hepatology and Endocrinology, Hannover</td>
</tr>
<tr>
<td>Romanski</td>
<td>Annette</td>
<td>Goethe University Frankfurt, Internal Medicine II, Haematology/ Oncology, Frankfurt</td>
</tr>
<tr>
<td>Rommelaeere</td>
<td>Jean</td>
<td>German Cancer Research Center, Tumor Virology, Heidelberg</td>
</tr>
<tr>
<td>Roppelt</td>
<td>Verena</td>
<td>Goethe University Frankfurt, Institute for Molecular Biosciences, Frankfurt</td>
</tr>
<tr>
<td>Rothe</td>
<td>Michael</td>
<td>Hannover Medical School, Institute of Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Ruggiero</td>
<td>Eliana</td>
<td>National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) Translational Oncology, Heidelberg</td>
</tr>
<tr>
<td>Sallach</td>
<td>Jessica</td>
<td>University Hospital of Cologne, Clinic I of Internal Medicine, Center for Molecular Medicine Cologne (ZMMK), University of Cologne Laboratory for AAV Vector Development, Cologne</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Salmikangas</td>
<td>Paula</td>
<td>Finnish Medicine Agency, Committee for Advanced Therapies (CAT), Helsinki, Finland</td>
</tr>
<tr>
<td>Salva</td>
<td>Emine</td>
<td>Marmara University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Istanbul</td>
</tr>
<tr>
<td>Salzig</td>
<td>Denise</td>
<td>University of Applied Science Mittelhessen, Institute of Bioprocess Engineering and Pharmaceutical Technology, Giessen</td>
</tr>
<tr>
<td>Sanzenbacher</td>
<td>Ralf</td>
<td>Paul-Ehrlich-Institut, Tissue Engineering, Somatic Cell Therapeutics, Langen, Germany</td>
</tr>
<tr>
<td>Schambach</td>
<td>Axel</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Schanda</td>
<td>Julia</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Scheding</td>
<td>Stefan</td>
<td>Stem Cell Center, Lund University, Sweden</td>
</tr>
<tr>
<td>Schepers</td>
<td>Aloys</td>
<td>Helmholtz Center Munic, German Research Center for Environment Health, Munic</td>
</tr>
<tr>
<td>Schlenke</td>
<td>Peter</td>
<td>University Hospital Muenster, Institute of Transfusion Medicine and Transplantation Immunology, Muenster</td>
</tr>
<tr>
<td>Schmeer</td>
<td>Marco</td>
<td>PlasmidFactory GmbH &amp; Co. KG, Bielefeld</td>
</tr>
<tr>
<td>Schmidt</td>
<td>Tobias</td>
<td>University Hospital Bonn, Institute for Clinical Chemistry and Pharmacology, Bonn</td>
</tr>
<tr>
<td>Schmiermund</td>
<td>Alexandra</td>
<td>University of Applied Science Mittelhessen, Institute of Bioprocess Engineering and Pharmaceutical Technology, Giessen</td>
</tr>
<tr>
<td>Schmitt</td>
<td>Nadine</td>
<td>University Hospital Muenster, Institute of Transplantation Medicine, Muenster</td>
</tr>
<tr>
<td>Schnüttgen</td>
<td>Frank</td>
<td>Goethe University Frankfurt, Molecular Hematology, Frankfurt am Main</td>
</tr>
<tr>
<td>Scholz</td>
<td>Simone</td>
<td>German Cancer Research Center, Translational Oncology, Heidelberg</td>
</tr>
<tr>
<td>Schrezenmeier</td>
<td>Hubert</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute Ulm, Ulm</td>
</tr>
<tr>
<td>Schwäble</td>
<td>Joachim</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Schüttrumpf</td>
<td>Jörg</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Seebach</td>
<td>Caroline</td>
<td>Goethe University Frankfurt, Department of Trauma-, Hand- and Reconstructive Surgery, Frankfurt</td>
</tr>
<tr>
<td>Seeger</td>
<td>Florian</td>
<td>Goethe University Frankfurt, Institute for Cardiovascular Regeneration, Frankfurt</td>
</tr>
<tr>
<td>Seidl</td>
<td>Christian</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Seifried</td>
<td>Erhardt</td>
<td>German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Serve</td>
<td>Hubert</td>
<td>Goethe University Frankfurt, Internal Medicine II, Haematology/Oncology, Frankfurt</td>
</tr>
<tr>
<td>Sethe</td>
<td>Sebastian</td>
<td>Lawford Davies Denoon Ltd, London, UK</td>
</tr>
<tr>
<td>Sgodda</td>
<td>Malte</td>
<td>Hannover Medical School, REBIRTH group Stem Cell Biology, Hannover</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>---------------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Shevchenko</td>
<td>Evgeny</td>
<td>Russian Cardiology Research and Production Center, Moscow</td>
</tr>
<tr>
<td>Sieben</td>
<td>Maike</td>
<td>Johannes- Gutenberg University Mainz, Department of Internal Medicine I, Mainz</td>
</tr>
<tr>
<td>Singer</td>
<td>Heike</td>
<td>University Hospital Bonn, Institute of Experimental Hematology and Transfusion Medicine, Bonn</td>
</tr>
<tr>
<td>Singh</td>
<td>Martin</td>
<td>National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) Translational Oncology, Heidelberg</td>
</tr>
<tr>
<td>Stemberger</td>
<td>Christian</td>
<td>TU Munich, Institute for Medical Microbiology, Immunology and Hygiene, Munich</td>
</tr>
<tr>
<td>Stripecke</td>
<td>Renata</td>
<td>Hannover Medical School, Hematology, Hannover</td>
</tr>
<tr>
<td>Suessner</td>
<td>Susanne</td>
<td>Red Cross Blood Transfusion Service of Upper Austria, Linz, Austria</td>
</tr>
<tr>
<td>Swierczek</td>
<td>Marta</td>
<td>Paul Ehrlich Institut, Department of Medical Biotechnology, Langen</td>
</tr>
<tr>
<td>Thalheimer</td>
<td>Frederic B.</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Theobald</td>
<td>Matthias</td>
<td>Johannes- Gutenberg University Mainz, Department of Internal Medicine III (Hematology, Oncology, Pneumology), Mainz</td>
</tr>
<tr>
<td>Thieme</td>
<td>Sebastian</td>
<td>Dresden Faculty of Medicine Carl Gustav Carus, Technical University Dresden, Department of Pediatrics, Dresden</td>
</tr>
<tr>
<td>Thies</td>
<td>Verena</td>
<td>Hannover Medical School, Institute for Experimental Hematology, Hannover</td>
</tr>
<tr>
<td>Thrasher</td>
<td>Adrian</td>
<td>Centre for Immunodeficiency, Molecular Immunology Unit, Institute of Child Health, London, UK</td>
</tr>
<tr>
<td>Tischer</td>
<td>Sabine</td>
<td>Hannover Medical School, Institute for Transfusion Medicine, Hannover</td>
</tr>
<tr>
<td>Tjwa</td>
<td>Marc</td>
<td>German Red Cross Blood Donor Service Baden- Württemberg- Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Tonn</td>
<td>Torsten</td>
<td>German Red Cross Blood Donor Service East, Institute Dresden, Dresden Faculty of Medicine Carl Gustav Carus, Technical University Dresden</td>
</tr>
<tr>
<td>Tuddenham</td>
<td>Edward</td>
<td>University College London, UCL Cancer Institute, London, UK</td>
</tr>
<tr>
<td>Uchida</td>
<td>Shizuka</td>
<td>Max-Planck-Institute for Heart and Lung Research, Cardiac Development and Remodelling, Bad Nauheim</td>
</tr>
<tr>
<td>Uckert</td>
<td>Wolfgang</td>
<td>Max-Delbrück-Center for Molecular Medicine, Molecular Cell Biology and Gene Therapy, Berlin</td>
</tr>
<tr>
<td>Ungerer</td>
<td>Christopher</td>
<td>German Red Cross Blood Donor Service Baden- Württemberg- Hessen, Institute of Transfusion Medicine, Goethe University Frankfurt, Frankfurt</td>
</tr>
<tr>
<td>Vandendriessche</td>
<td>Thierry</td>
<td>Free University of Brussels, Brussels, Vesalius Research Center, Flanders Institute of Biotechnology; University of Leuven, Brussels/Leuven, Belgium</td>
</tr>
<tr>
<td>Velardi</td>
<td>Andrea</td>
<td>Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy</td>
</tr>
<tr>
<td>Vetter</td>
<td>Alexandra</td>
<td>Ludwig Maximilian University of Munich, Department of Pharmacy, Munich</td>
</tr>
<tr>
<td>Volk</td>
<td>Andreas</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Surname</td>
<td>First name</td>
<td>Organisation</td>
</tr>
<tr>
<td>---------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>von Kalle</td>
<td>Christof</td>
<td>National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) Translational Oncology, Heidelberg</td>
</tr>
<tr>
<td>von Melchner</td>
<td>Harald</td>
<td>Goethe University Frankfurt, Molecular Haematology, Frankfurt</td>
</tr>
<tr>
<td>Völker</td>
<td>Iris</td>
<td>Paul-Ehrlich-Institut, Molecular Biotechnology and Gene Therapy, Langen</td>
</tr>
<tr>
<td>Walisko</td>
<td>Oliver</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Weber</td>
<td>Axel</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Weber</td>
<td>Marlen</td>
<td>Max-Planck-Institute for Brain Research, Frankfurt</td>
</tr>
<tr>
<td>Weber</td>
<td>Kristoffer</td>
<td>University Medical Centre Hamburg-Eppendorf, Clinic for Stem Cell Transplantation Research Department Cell and Gene Therapy, Hamburg</td>
</tr>
<tr>
<td>Weigand</td>
<td>Julia</td>
<td>Goethe University Frankfurt, Institute for Molecular Biosciences, Frankfurt</td>
</tr>
<tr>
<td>Weiss</td>
<td>Katja</td>
<td>University of Applied Science Mittelhessen, Institute of Bioprocess Engineering and Pharmaceutical Technology, Giessen</td>
</tr>
<tr>
<td>Weisser</td>
<td>Maren</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Wels</td>
<td>Winfried</td>
<td>Biomedical Research Institute Georg-Speyer-Haus, Frankfurt</td>
</tr>
<tr>
<td>Wener</td>
<td>Carsten</td>
<td>Leibniz Institute of Polymer Research Dresden, Dresden</td>
</tr>
<tr>
<td>Wildner</td>
<td>Oliver</td>
<td>Paul-Ehrlich-Institut, Langen</td>
</tr>
<tr>
<td>Wintterle</td>
<td>Sabine</td>
<td>Hannover Medical School, Institute for Nephrology, Hannover</td>
</tr>
<tr>
<td>Wittmann</td>
<td>Alexander</td>
<td>Goethe University Frankfurt, Institute for Molecular Biosciences, Frankfurt</td>
</tr>
<tr>
<td>Woods</td>
<td>Niels-Bjarne</td>
<td>Department for Molecular Medicine and Gene Therapy, Institute of Laboratory Medicine, Lund University, Lund, Sweden</td>
</tr>
<tr>
<td>Zeiher</td>
<td>Andreas</td>
<td>Goethe University Frankfurt, Internal Medicine III, Cardiology, Frankfurt</td>
</tr>
<tr>
<td>Zhou</td>
<td>Qi</td>
<td>Paul-Ehrlich-Institut, Molecular Biotechnology and Gene Therapy, Langen</td>
</tr>
</tbody>
</table>
Exhibition Plan Ground Floor

<table>
<thead>
<tr>
<th>Company</th>
<th>City</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>CellGenix GmbH</td>
<td>D-79108 Freiburg</td>
<td>103</td>
</tr>
<tr>
<td>Consarctic GmbH</td>
<td>D-63821 Schöllkrippen</td>
<td>100</td>
</tr>
<tr>
<td>eBioscience</td>
<td>A-1030 Vienna</td>
<td>111</td>
</tr>
<tr>
<td>Miltenyi Biotec GmbH</td>
<td>D-51429 Bergisch Gladbach</td>
<td>102</td>
</tr>
<tr>
<td>PeproTech GmbH</td>
<td>D-22081 Hamburg</td>
<td>110</td>
</tr>
<tr>
<td>PlasmidFactory GmbH &amp; Co. KG</td>
<td>D-33607 Bielefeld</td>
<td>101</td>
</tr>
<tr>
<td>Vibalogics GmbH</td>
<td>D-27472 Cuxhaven</td>
<td>105</td>
</tr>
</tbody>
</table>
Exhibition Plan 1st Floor

Poster Exhibition
**Arriving by public transport:**

**Coming from Hauptwache**
- take line(s) U1, 2, 3, 8 to „Holzhausenstraße“, then walk for appr. 300 meters across Bremer Straße towards the campus (entrance „Bremer Straße“)

**Coming from Frankfurt Hauptbahnhof**
- take line U4, get off at „Bockenheimer Warte“ or
- take bus line 64 to „Bremer Straße“ (appr. 11 minutes) or
- take bus line 75 to „Uni Campus Westend“, get off at „Lübecker Straße“ for „Hörsaalzentrum“ or „Bremer Straße“ for „Anbau Casino“ or „Uni Campus Westend“ for Main Building.

**Coming from Westbahnhof**
- take bus line 36 (Hainer Weg), get off at „Campus Westend/Universität“ (appr. 15 minutes)

**Arriving by car:**
- At Autobahnkreuz „Nordwestkreuz Frankfurt“ (A5/A66) take A66 towards F-Stadtmitte/Miquelallee.
- Entering Frankfurt City limit the Autobahn leads straight into Miquelallee.
- Turn right at the first traffic light into Hansaallee.
- Leave Hansaallee at the second traffic light and turn right into Bremer Straße.
- Make another right turn at the next traffic light into Fürstenberger Straße.
- After 200m you will find the university on the right hand.

Parking at the Campus Westend is due to limited parking space and construction areas not possible.
Please use the Parkhaus Palmengarten, Siesmayerstraße 61, 60323 Frankfurt am Main
Public Transportation
The official Journal of the AABB, **TRANSFUSION** presents submissions concerning tissue transplantation and hematopoietic, cellular, and gene therapies in addition to blood banking and transfusion medicine topics.

www.transfusion.org

The official Journal of the ISBT, **Vox Sanguinis** reports on important, novel developments in transfusion medicine.

www.voxsanguinis.com

The official Journal of the BBTS, **Transfusion Medicine** publishes articles on transfusion medicine in its widest context.

www.transfusionmedjournal.com

The Journal of Gene Medicine publishes high quality original articles and reviews on the science of gene transfer and its applications in gene and cell therapy.

www.journalofgenemedicine.com

The journal **Journal of Tissue Engineering and Regenerative Medicine** focuses on the development of biological functional substitutes that restore, maintain, or improve tissue or organ function.

wileyonlinelibrary.com/journal/term

**JCMM** publishes basic research that furthers our understanding of the cellular and molecular mechanisms of disease and translational studies that convert this knowledge into therapeutic approaches.

www.jcmmjournal.com

Access all these Journals now on **WILEY ONLINE LIBRARY**